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Background: In July 2014, New York State became the 23rd state to legalize marijuana 
(“cannabis”) for medical consumption under the New York State Medical Marijuana Program 
(“Program”). Three years later, during his Executive budget address, the NYS Governor, 
Honorable Cuomo, directed the Department of Health in consultation with other NYS agencies, 
to evaluate the experience, consequences and effects of legalized marijuana in neighboring states 
and territories, and to review the health, criminal justice and economic impacts of regulating 
marijuana use. That report concluded that the positive effects of a regulated marijuana market 
outweighed the potential negative impacts.   
Objective: This dissertation has three aims. First, to study emerging trends in the 
experiences of a convenience sample of 12 stakeholders accessing and utilizing the New York 
States’ Program.   
Second, to study the cost-effectiveness of medical cannabis in combination with the 
opioid pharmacotherapy compared to the standard of care employing opioids alone from a 
healthcare perspective with a time horizon of one year, in 2017 US$, with quality adjusted life 
years gained as the primary outcome.   
Third, to study the lived experiences of a cohort of 20 subjects with cancer-related 
neuropathic pain who are generally being managed on opioid pharmacotherapy for cancer-
related pain in whom medical cannabis has been added to improve analgesia and diminish opioid 
requirements. 
Methods:  Approval was given by the City University School of Public Health, Human 
Research Protection Program for research designs to address the three study objectives.   
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The first study was designed as a qualitative cross-sectional study of stakeholders of 
Vireo Health dispensaries in downstate New York that comprised entrepreneurs, physician 
providers, pharmacists, and client stakeholders. In-depth, semi-structured phone interviews were 
conducted following a topical guide instrument with major domains of stakeholders’ personal 
views, community norms, attitudes, and behaviors, prescribing practices, knowledge of drug 
cost, insurance coverage, and financial subsidies, pharmacy and dispensing processes. Primary 
data was analyzed on Dedoose® with the compilation of a codebook and coding of transcripts to 
yield emergent themes that were in turn triangulated.  
The second study was designed as a cost-effectiveness analysis using a decision tree in 
TreeAge Pro to simulate the cost and clinical outcomes of adding medical cannabis treatment for 
chronic sickle cell disease pain compared to the standard of care using opioid analgesic 
medication alone. Probabilities, costs, and quality of life utility weights associated with opioid 
use and chronic pain among patients treated with medical cannabis versus standard of care were 
derived from published literature. Primary outcomes included medication costs and health-
related quality of life (measured in adjusted life years, QALYs). The analysis was carried out 
from a healthcare sector perspective with a time horizon of one year. Medication costs associated 
with chronic pain treatment involving cannabis and opioids expressed in 2017 US$. Incremental 
cost-effectiveness ratios were calculated by comparing cannabis-assisted treatment with opioid-
only standard of care. One-way sensitivity analyses and threshold analyses were performed to 
assess parameter uncertainty.    
The third study was designed as a qualitative cohort study of the lived experiences of a 
convenience sample of subjects who met the eligibility criteria of age 21 or older, English 
speaking, under the care of a pain management health provider, not pregnant or breast-feeding, 
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and the diagnosis of cancer-related neuropathic pain. Study subjects were all served by a single 
upstate Vireo Health dispensary to add medical cannabis to a standard of care regimen to 
improve analgesia and reduce the need for opioids. The subjects underwent semi-structured in-
depth phone interviews using a topic guide covering domains related to experiences of cancer 
and treatment, experiences and perceptions of pain management strategies, and impacts on 
quality of life. Thematic analysis was conducted with coding by hand using Microsoft Word. 
Coded excerpts were copied into a themes matrix in Excel where emerging trends were critically 
analyzed according to the study aims.     
Results: Chapter 2 studied 12 stakeholders of the New York State Medical Marijuana 
Program and revealed emergent themes centered on facilitators and barriers for the acceptance, 
accessibility and use of medical marijuana in New York. Facilitators included effectiveness and 
safety, while barriers included stigma, process, and cost. The effectiveness of medical marijuana 
as a medication for various conditions and was highlighted as a major facilitator for its 
legalization, acceptance, and use). Additionally, participants noted the demonstrated safety of 
marijuana as a medication, which has shown to be much safer than other legal drugs, and its use 
in helping patients come off opioids. Stigma surrounding marijuana was identified as a barrier 
with participants highlighting misperceptions or personal stigmas as a prohibitive to legalization, 
acceptance, and use. There was frank criticism of NYS’ program by stakeholders evident in other 
themes emerging around the processes involved in accessing and using the NYS Program.  
Entrepreneurs were critical of the excessively bureaucratic process of the application and 
registration process for opening dispensaries; and physicians were wary of the Program’s 
educational bureaucratic program to become certified providers; and clients cited difficulty in 
finding providers, assembling documentation, registering on the Program website, waiting for the 
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certification card, arranging a pharmacist consultation at the dispensary, and among those 
perceived stigmas of cannabis. Additionally, the cost of medical cannabis was voiced as 
excessive by patients.  
Chapter 3 study of the cost-effectiveness of adding medical cannabis treatment for 
chronic sickle cell disease pain compared to the standard of care using opioid analgesic 
medication alone found that cannabis-assisted treatment is estimated to reduce addiction by 
11.5% among SCD patients previously addicted to opioids and improve chronic pain control 
from 56% to 76%. On average, cannabis-assisted treatment increased monthly pain management 
medication costs by $1781.21 per person compared to opioid analgesic treatment alone 
($6037.61 vs. $4,256.40) and produced 0.06 more QALYs per person (0.58 vs. 0.52 QALYs). 
The resulting incremental cost-effectiveness ratio was $27,219.78/QALY gained. Based on a 
commonly used $100,000/QALY willingness-to-pay threshold, cannabis-assisted treatment was 
very cost-effective compared to the opioid-only strategy. Sensitivity analyses suggested that 
these results were robust against a wide range of parameter values. 
Chapter 4 studied the use of medical cannabis in the management of cancer-related pain 
from a single dispensary experience in upstate New York among 8 men and 12 woman with a 
mean age 59.5 years with cancer-related neuropathic pain associated with lymphoproliferative 
tumors, malignant cancer of the breast, lung, ovary, prostate, gallbladder, and skin. The majority 
of subjects (80%) were taking opioid pharmacotherapy to treat severe neuropathic pain scored by 
PEG and VAS (in 7 subjects) respectively 5.7/10 and 4.25/5 consistent with severe neuropathic 
pain before adding oral (7 subjects), sublingual (2 subjects), or inhaled cannabis products (4 
subjects), or in combination (7 subjects). The employment status was known in 18 subjects, 14 of 
whom were not working due to disease disability (8 subjects) or retirement (6 subjects) while 4 
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others were working full-time (3 subjects) or part-time (1 subject). Emergent themes related to 
the experiences of cancer and its treatment, perceptions and experiences of pain management 
strategies, perceived benefits of medical cannabis, enablers of improved pain management, and 
barriers to pain management.  There was variability between and within individual’s experiences 
of cancer pain and management strategies. Subjects often reported that opioid-based medications 
fell short of providing sufficient pain control, were associated with severe or debilitating side 
effects, or a mixture of the two. Cannabis-based medication provided a socially accepted, safe 
and well-tolerated alternative to opioids in this cohort. The foremost challenge of the cohort was 
in formulating their own strategy of pain management, combining available multimodality 
aspects. Reported enablers for this included the availability of knowledge around cannabis-based 
medication and their uses, as well as, moral, logistical, and financial support structures. Major 
barriers to cannabis-based medication highlighted challenges resulting from its yet full 
integration into the nation and state’s health systems that instilled inconsistencies in guidance, 
access, and financial costs. 
Discussion: New York State’s Program vertically integrates legislative and public health 
policy of the positive effects of a regulated marijuana market in NYS that favorably influences 
the optimal functioning of dispensaries, and outweighs its potential negative impacts to society, 
communities, or individuals. However, there are significant barriers to stakeholders including 
entrepreneurs, prescribing physicians and patients, even when they conform to state-mandated 
program policies. This applies to dispensary ownership, provider and patient certification, and 
accessing cannabis. There is stigmatization related to the acceptability of medical cannabis even 
in the diseases for which it may be approved and deemed cost-effective, compared to the 
standard of care therapies.  
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Conclusion:  The present dissertation compiles qualitative and quantitative public health 
research based upon New York State’s Medical Marijuana Program. Viewed through the lens of 
public health and a socioecological framework model, medical cannabis policy in New York 
State should be framed, emphasizing it as an alternative to opioid pharmacotherapy in serious 
disorders such as cancer- and sickle cell disease-related neuropathic pain, in which there is 
favorable cost-effectiveness. Local communities and dispensaries can help frame acceptance 
according to the principles of social reconstruction that highlight the interdependence of social, 
environmental and individual biological determinants. At the societal level, there must be 
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 When the coronavirus (CoV) 2019 (COVID-19) pandemic struck in late February 2020, I 
was certain it would undo my doctoral dissertation. Looking back, I was preparing for this long 
before it struck.  In November 2019, I released the book, The Autoimmune Brain, a compendium 
of autoimmune neurologic diseases triggered by infection that share “I-cubed” (I3), a shorthand 
for post-infectious autoimmunity. I-cubed autoimmune disorders result from the multiplier effect 
of infection, immunity and inflammation. That is, when protective immunity becomes the source 
of autoimmunity, conditioned by applicable environmental and genetic predisposing factors. This 
is precisely the problem in CoV infection, which leads the immune response to go out of control 
with potentially fatal outcomes depending upon host factors. Writing this dissertation in the 
setting of the COVID-19 pandemic reminds me of my study subjects in Chapter 4, who are the 
major combatants in this struggle because of their comorbid disease and at greatest risk of 
potentially fatal contagion due to a compromised immune system.  Further research is needed to 
explore the transmission and pathogenic mechanism of the CoV, and to clarify the evolutionary 
path from the original host to cross-species transmission and prevent another novel crossover of 
CoV from animals to humans. Other vital areas are to uncover the molecular mechanism of viral 
entry and replication to fuel the development of targeted antiviral drugs and vaccines. I dedicate 
this dissertation to my family who kept me on track to finish this dissertation during this 
challenging period.    
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Chapter 1: Introduction   
Cannabis-Based Medication 
“Marijuana” is the common (and legal) term for the dried flowers and leaves of the plant 
Cannabis (C.) sativa (cannabis), and for the plant itself. The flowers contain concentrated 
amounts of chemicals known as cannabinoids (produced only by this plant), terpenoids, and 
flavonoids, the amount and mix of which vary with plant genetics, growing practices, and timing 
of its harvest. It is one of the earliest plants cultivated by man for medicinal purposes (4).  
Ancient Chinese cite cannabis in their pharmacopoeia as pen-tsar chin in the first century as an 
anesthetic for surgery. Hindu Sanskrit texts cite it as a sacred plant called gañjā, derived from 
flowers of the dry leaves of the sativa plant. The ensuing centuries saw the spread of cannabis to 
the Middle East, Africa and Arabia, where physician texts cited it as a pain reliever and cleanser 
of the brain. Later, 19th century physicians in Ireland and France (5, 6) delineated its analgesic 
and psychoactive properties prior to recognizing its exact chemical structure and mechanism of 
action. At the turn of the century, pharmaceutical companies in Germany, England and the 
United States (US) (7) marketed products containing extracts of marijuana as “herbal cannabis” 
and hashish, which were made by extracting cannabinoid-rich factors as a resin, while the term 
“cannabis” remained a catchall term to the present, that includes both products.  
 The pharmacologic effects of cannabis-based medications (CBM) are attributed to the 
actions of (-)-Trans-delta-9-tetrahydrocannabinol (THC) (8-14). Cannabidiol or CBD, equipotent 
on cannabis type1 (CB1) receptors in the brain, and at opioid receptors in peripheral sensory 
neurons, synergistically target the affective qualities of pain to enhance analgesia (15-17).   Two 
US Food and Drug Administration (FDA)-approved cannabinoid drugs available for prescription 
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in the US: dronabinol (Marinol) Ⓡ, a synthetic THC compound, and nabilone (Cesamet Ⓡ), a 
semisynthetic analog of Δ9-THC with an approximately 10 times greater potency than 
dronabinol. While such drugs have shown some efficacy as an adjuvant analgesic, the sedating 
and psychotropic properties of both agents limits their utility. 
Nabiximols (Sativex Ⓡ), an oral spray that is an approximately racemic mixture of THC and 
CBD, is approved for opioid-resistant, treatment-refractory cancer pain. It is a useful add-on 
analgesic for patients with opioid-refractory cancer pain at low and medium doses.  
The past two decades have witnessed extraordinary advances in the analgesic benefits of 
cannabis-based medications employing randomized clinical trials (RCT) and meta-analyses 
thereof. In 1999, the Institute of Medicine (IOM) assessed the medical value of medical cannabis 
noting that opioid analgesic medications were limited by dose-related side effects and the 
development of tolerance or dependence (18). The authors reviewed data from three double 
blind, placebo-controlled RCT of cancer pain resistant to opioids (19). The studies cited 
analgesia and pain relief by 10 mg of THC or its analogues in pill form equal to 60 mg of 
codeine (20-22).  In 2014, Koppel and colleagues (23) conducted a systematic review of RCTs of 
cannabis-based medications through 2013 in the treatment of central pain, categorizing them 
Class I to IV, from most to least robust according to the American Academy of Neurology (24). 
The authors identified three prospective cohort (Class I) studies (25-27) of the efficacy of CBD 
and THC alone or together in varying ratios, citing its efficacy.  
In 2017, Aviram and Samuelly-Leichtag (28) conducted a systematic review and meta-
analysis of published RCT up to 2015 in the treatment of neuropathic pain using any type of 
CBM. Their analysis showed a reduction in pain of 20% to 50% compared to placebo. That same 
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year, investigators at the National Academy of Science issued a report on the health effects of 
cannabis and cannabinoids (29). The report included a review of two RCT of the treatment of 
chronic pain due mainly to neuropathy, cancer, or multiple sclerosis, with cannabinoids and 
synthetic THC (30, 31), noting a 40% increased odds for improvement compared to controls, 
with effects that did not differ across pain conditions.        
There is an urgency to integrate CBM into the multidisciplinary approach to chronic pain. 
Hill and colleagues (32) reviewed the use of CBM noting that disorders associated with pain 
ranked fifth among conditions cited by the Global Burden of Disease Study in 2010 (GBD 2010) 
as a cause of years lived with disability (YLD) (33), accounting for a significant loss of QoL. 
Two studies (34, 35) showed two to three-fold higher levels of use of healthcare services in 
people with chronic pain than those without; and affected individuals cite modest clinically 
relevant benefit from any one pharmacologic intervention in combating chronic pain (36), 
suggesting the need for a multidisciplinary approach (37). 
Several studies have addressed the use of CBM to reduce physician and patient reliance 
on opioid pharmacotherapy in an effort to stem the growing opioid crisis. A 2014 National 
Institute on Drug Abuse (NIDA)-funded study by Bachhuber and colleagues (38) developed 
regression models of state and year fixed effects to examine percentage mean difference in age-
adjusted opioid mortality rates per 100.000 population across states that failed to enact medical 
cannabis laws, or did so prior to, or between 1999 and 2010. The authors reported lower rates of 
overdose mortality that strengthened over time, from 19% in year 1, to 33% by year 6. These 
results suggest that enactment of laws to allow for use of cannabis-based medications should be 
part of a comprehensive package of policies to stem the opioid crisis. A second NIDA-funded 
study by the RAND Corporation in (39) compared changes in opioid-related mortality and 
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treatment admissions in states adopting medical marijuana laws to those not adopting these laws. 
The study combined a traditional difference-in-differences framework with descriptive national 
vital statistics. It first replicated the results of Bachhuber and colleagues (38), and then extended 
the analysis sample to include three more years of data (adding 2010 to 2013).  In doing so, the 
authors were surprised to find that late law adopters contributed to a further decline in opioid 
overdose death rates from 2010 to 2013, due to the sale of CBM to qualified patients only. 
The anticipated cost-savings and improvement in patients’ QoL are also compelling 
reasons to make CBM available in all states. Using data on all prescriptions filled by Medicare 
Part D enrollees from 2010 to 2013 Bradford and (40) examined prescription drugs for which 
marijuana could serve as a clinical alternative, including chronic pain in seventeen states and the 
District of Columbia. The authors used a simple difference-in-differences regression framework 
to estimate each category of prescription drug use and found an overall national reduction in 
Medicare program and enrollee spending of $165.2 million, with the highest component due to 
analgesic drug use. If the remaining states were to have adopted a medical marijuana law by 
2013, total spending by Medicare Part D would have been an estimated $468.1 million less, or 
0.5% of all Medicare Part D spending in 2013. 
 
Neuropathic Pain 
 Neuropathic pain is regarded as pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system.  Central neuropathic pain originates from damage to the 
brain or spinal cord, while peripheral neuropathic pain stems from damage to the peripheral 
nerve, plexus, dorsal root ganglion, or roots. Is further characterized by pain in the absence of a 
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noxious stimulus and may be spontaneous or evoked by sensory stimuli such as the light touch of 
the skin resulting in allodynia.  An array of potential pain mechanisms may be causative in a 
given individual reflecting a combination of central and peripheral nervous system pathways. 
Deconstructing neuropathic pain phenotypes shows an interplay of genetics, plasticity, neuronal 
cognitive, autonomic and neuroimmunologic interactions and modulation. 
A best estimate of the prevalence of pain with neuropathic characteristics in the general 
population is 6.9% to 10%, with more precise estimates for specific associated conditions. 
Neuropathic pain ranked fifth among conditions cited by the Global Burden of Disease Study in 
2010 (GBD 2010) for YLD (41), further accounting for loss of QoL, employment, and increased 
health costs. The most successful approaches to the treatment of neuropathic pain rely upon the 
multidisciplinary rather than any one intervention (18, 23). Available pharmacologic 
interventions topical lidocaine patch or low-concentration topical capsaicin, pain modulation 
with antidepressants like duloxetine and amitriptyline (Elavil Ⓡ), or antiepileptics like 
gabapentin (Neurontin Ⓡ) or pregabalin (Lyrica Ⓡ), but the proportion of patients who achieve 
at least 50% relief is generally 10% to 25% more than with placebo (42).  
Endocannabinoids serve as synaptic circuit breakers, regulating multiple physiological 
and pathological conditions including central and peripheral neuropathic pain. They use the 
brain's own cannabis-like substances, sharing the same molecular target as THC, the main 
psychoactive component in cannabis. The benefit of cannabinoids in the management of 
neuropathic pain is their favorable modulation of cognitive and autonomic processing and brain 
signaling seen in chronic pain states, and their capacity to suppress behavioral responses to 
noxious stimulation and nociceptive processing. The frontal-limbic distribution of CB1 receptors 
in the brain suggests that cannabinoids preferentially target the affective qualities of pain. In 
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addition, cannabinoids may attenuate low-grade inflammation, another postulate for the 
pathogenesis of neuropathic pain). Perhaps the most compelling reason to define the role of 
CBM for control of pain and legalization of their use in all states is to reduce physician and 
patient’s reliance on opioid pharmacotherapy for the treatment of chronic neuropathic pain.     
The causes of neuropathic pain can be triggered by endocrinologic (diabetes and thyroid 
disease), connective tissue diseases (lupus, Sjogren syndrome), infectious (malaria) and post-
infectious autoimmune disorders (human immunodeficiency virus type 1 [HIV-1), Lyme disease, 
syphilis, tuberculosis, herpes), genetic disorders (Fabry disease), and cancer (carcinoma, 
lymphoma) each with a specific treatment. However, the resulting pain associated with each is 
treated similarly according to 2016 standard clinical practice guidelines (43) beginning with 
topical lidocaine, compound creams, and capsaicin patches, and progressing to oral tricyclic 
antidepressants (TCA), pregabalin, and gabapentin, and later incorporating opioids. Regardless 
of the order of first-, second- and third-line agents, The Second European Federation of 
Neurological Societies Task Force found similar efficacy for most agents alone and in 
combination using a Cochrane Database and Medline search class I and II RCTs (44).  More 
recently, medical cannabis emerged as an alternative in patients with non-cancer and cancer-
associated neuropathic pain who do not respond well to opioids or have side effects from the use 
of traditional analgesics (45).   
An analysis of 29 subjects with severe chronic pain approved for medical cannabis in 
New York State (46) associated with spinal cord injury (20 subjects), cancer (3 subjects), 
neuropathy (3 subjects), inflammatory bowel disease (2 subjects), and Parkinson disease (1 
subject) responded favorably in primary outcome measures of pain quality, with significant 
reduction in opioid consumption and cost-savings. However, this study was limited by its 
21 
 
retrospective nature, bias of small sample size and inclusion of a small number of unrelated 
causes primarily spinal cord injury that limited its generalization to cancer or neuropathic pain.  
Since the inception of the NYS Medical Marijuana Program (47) there has been only one 
publication from the Department of Health, Wadsworth Center in Albany reporting on its status 
(48) and that described product analysis. There has not been a review of its performance or 
receptivity of dispensary stakeholder to date. Nor has there been a detailed analysis of its 
performance in the management of neuropathic pain in particular cancer-related chronic pain. 
Both of these represent gaps in the medical literature, which will be addressed in the present 
dissertation.  
 
Opioid-Based Medication      
  Opioid analgesic drugs often referred to as “opioids” or “narcotics” have the propensity 
for both abuse and medicinal use (49). With pharmacologic properties similar to those of 
morphine, they are highly lipophilic and pass readily across nasal membranes as well as the 
blood-brain barrier where they act at opiate mu receptor agonists leading to euphoria and 
analgesia (50). This has led to their widespread use in treating pain in the last two decades. 
Opioids have become the most widely prescribed class of drugs in the US, with an estimated 245 
million new prescriptions being filled in 2014 (51). However, rates of abuse have risen 
dramatically. According to the most recent National Survey on Drug Use and Health (52) 11.8 
million people (over 4% of the population) in 2016, aged 12 years or older in the US misused 
prescription opioid drugs. In 2015, overdoses from both licit and illicit opioids resulted in over 
33,000 deaths (45) and 750,000 emergency room (ER) visits were attributed to opioid abuse, making 
it a significant public health burden. Further, patients who divert or abuse their opioid analgesic 
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medications complicate long-term opiate prescribing. Overuse or abuse of opioids have fueled 
the acronym opioid epidemic (53, 54). This ongoing epidemic lies at the nexus of two public 
health challenges; improving patients’ health related QoL (HRQoL) through effective pain 
management and reducing the growing burden and harm caused by abuse of these drugs. 
Four historical developments have influenced the acceptance and availability of opioid 
analgesic drugs in the US. First, the easing of restrictions governing the prescription of opioid 
analgesic drugs by physicians for chronic pain treatment by state medical boards, in a process 
that started in 1998 (49). Second, efforts beginning in the 1990s by the American Pain Society, 
and two decades later by medical professionals (55) and the IOM (56) to recognize and reframe 
pain management. Third, the availability of both opioid analgesics to treat pain and opioid 
antagonists to treat opioid dependence (57). Fourth, the establishment of guidelines by the 
Centers for Disease Control and Prevention (CDC) in 2016, for the safe dispensation of opioid 
analgesic drugs by community primary care providers (58) and not just by pain management 
experts. A year later, evidence-based standards of the Joint Commission of the Accreditation of 
Healthcare Organization were published to improve the care of patients taking opioid analgesic 
drugs for chronic pain (59), updating those of a decade earlier (60). 
     As a syndrome, pain is complex to understand, diagnose and manage and it is often 
further complicated by comorbidities (61) such as diabetes and cancer which can make its 
treatment more challenging.  The added complexity presented by the potential for addiction and 
side effects of opioids further complicate pain management.  
 Although preclinical evidence suggests cannabinoids increase the analgesic effect of 
opioids, thus requiring a lower dose to achieve relief (62) a systematic review and meta-analysis 
(63) showed inconsistent results in the opioid sparing effect of CBM, especially in cancer, biased 
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in part by patients who may favor lower doses of CBM to avoid drug side-effects (64) and 
physicians who discourage opioid dose reduction to maintain effective analgesia (65). This gap 
in the literature of patient receptivity of CBM to improve analgesia independently and as 
adjuvant therapy with opioids will be explored in this dissertation where the observational 
analysis takes place outside of the RCT at the dispensary level.  
        
Aims  
 Three study aims below have the overarching goals of understanding New York State’s 
Medical Marijuana Program including its cost-effectiveness, potential for reducing opioid needs 
with CBMs, and understanding the lived experiences of stakeholders in New York State may 
give insights into affecting the opioid epidemic.  
Aim 1: To study emerging trends in the experiences of a convenience sample of 12 key 
stakeholders accessing and utilizing the medical marijuana program in NYS through Vireo 
Health, Inc. The study participants will be identified by Vireo Health, chosen for their 
willingness to participate in a research protocol without expectation of compensation for an in-
depth semi-structured interview including dispensary entrepreneurs, prescribing physicians, 
pharmacists, and patients filling medical cannabis prescriptions in one or more dispensaries 
managed by Vireo Health. Salient topics will include facilitators and barriers in the NYS 
Medical Marijuana Program’s implementation process, and the registration paths for a referring 
provider and the registration of qualifying patients. 
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Aim 2: To study the cost-effectiveness of adding medical cannabis to opioid analgesic 
medication in the management of chronic pain in patients with sickle cell disease using a 
decision tree model analyzed in TreeAge Pro to simulate the cost and clinical outcomes.  
Probabilities, costs, and quality of life utility weights associated with opioid use and chronic pain 
among patients treated with medical cannabis versus the standard-of-care are derived from 
published literature. Primary outcomes include medication costs and health-related quality of life 
(measured in adjusted life years, QALYs). The analysis is carried out from a healthcare sector 
perspective with a time horizon of one year. Medication costs associated with chronic pain 
treatment involving cannabis and opioids are expressed in 2017 US$. Incremental cost-
effectiveness ratios are calculated by comparing cannabis-assisted treatment with opioid-only 
standard-of-care. One-way sensitivity analyses and threshold analyses are performed to assess 
parameter uncertainty .   
Aim 3: To study the lived experiences of a convenience sample of 20 subjects with 
cancer-related neuropathic pain who are generally being managed with opioids and who will be 
adding medical cannabis to their regimen to improve analgesia and diminished opioid 
requirements. Study subjects, all served by a single dispensary of Vireo Health located in 
Binghamton, New York will undergo in semi-structures depth phone interviews to probe their  
lived experienced from which emergent will be triangulated with their self-reported experiences 
with CBM as an adjunctive pharmacotherapy to opioids in the management of their cancer-






Theoretical Framework  
 The socioecological framework (SEF) model (Figure 1) conceptualizes the hierarchy of 
society, community, interpersonal and individual factors affecting a public health problem. At 
the societal level, there are legislative and health policy factors that present barriers or facilitate 
access to medical cannabis in local community dispensaries. These policies can create the 
environment in which prescribing norms and standards of care operate at the organizational level 
within dispensaries and in communities. It is also at this level that one can examine the 
mechanisms and processes through which prescribing physicians and treated patients conform to 
state policies regarding medicinal marijuana. Stigma and social norms operate at both 
community and intrapersonal levels relating to acceptability of pain management options such as 
opioids and CBM, wherein the HRQoL measures are used to describe the impact of chronic.  At 
the individual level, the patients themselves and their experiences are considered.  
 The goal of this dissertation is to provide current scientific and health perspective data of 
medical marijuana to inform the public and build support for its regulated use.  The author has 
studied marijuana for several years, however the information contained in this dissertation is 
only a fraction of what is currently known as it addresses essential gaps in our knowledge. The 
study in Chapter 2 explores stakeholders’ lived experiences in multiple downstate New York 
dispensaries under the management of Vireo Health, and examining facilitators and barriers of 
New York State’s Medical Marijuana Program and the use of CBM as an adjunct to the 
treatment of neuropathic pain. There has not been a previous study of the performance of this 
Program so it provides meaningful data to this literature gap. The study in Chapter 3 addresses 
the cost-effectiveness of adding medical cannabis to opioid analgesic medication in the 
management of chronic pain in patients using the example of sickle cell disease. It uses a model 
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and decision tree analysis derived from literature assumptions with a limited time horizon and 
2017 US$.  There has not been a study of this type in sickle cell disease, nor has  there been a 
study comparing the cost-effectiveness of cannabis-assisted treatment in managing chronic pain 
compared to the standard-of-care of opioid pharmacotherapy in various states of opioid addiction 
and dependency. With legalized use of medical cannabis, there will be research opportunities to 
address opioid addiction in a controlled manner by choosing appropriate disease models such as 
sickle cell disease. Hence, the study in Chapter 3 paves the way for addressing this literature gap. 
The study in Chapter 4 prospectively explores the lived experiences of individuals with cancer-
related neuropathic pain in a single upstate New York dispensary offering insights into another 
spectrum of chronic neuropathic pain disorders due to diverse cancers, which also engender 
opioid dependency. However, unlike Chapter 3, this next study addresses the use of cannabis-
assisted therapy from a qualitative research focus in understanding the lived experiences of a 
cohort of subjects with cancer-related pain who use a single marijuana dispensary in upstate New 
York. Chapter 5 concludes with the limitations and strengths of the studies and their relevance 
for health policy and further addresses the topic of legalization of marijuana nationwide.  
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Figure and Legend  
Figure 1: The socioecological framework is a multilevel conceptualization of health that includes 






Chapter 2: An In-Depth Interview Study of Stakeholders in the New York State 
Medical Marijuana Program  
 
Abstract  
Background: New York State’s Medical Marijuana Program was launched in 2016 
allowing for the sale of medical marijuana products. However, there has not been a review of its 
performance.  
Objectives: A pilot study examining New York State’s Medical Marijuana Program was 
undertaken to assess the experience and gaps in its performance from the standpoint of 
dispensary prescribing physicians, dispensary pharmacists, patients, educators and entrepreneurs.  
Methods: Semi-structured, in-depth interviews were administered to a cohort of 12 
subjects from various locations in the 5 boroughs of New York City and elsewhere in New York 
State, including 4 prescribing physicians, 4 pharmacists, 2 patients, 1 educator and entrepreneur. 
The data was analyzed using Dedoose for the determination of emergent themes.  
Results: Several themes emerged overall and within three distinct areas of the 
implementation process for the application and registration process for opening dispensaries, the 
registration process for a referring provider and the registration of qualifying patients notably 
“effective” and “safe” as facilitators, and “stigma” as a barrier. The code “Safe” identified areas 
where participants spoke about the demonstrated safety of marijuana as a medication, which has 
shown to be much safer than other legal drugs, including being used to help patients come off 
opioids. It was also used to highlight areas where participants noted that legalized versions or the 
drug is even safer because they are regulated.  
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Discussion: The themes that emerged from the interviews highlight tensions in the 
Program. While tightly regulating the process of certification for all stakeholders (physicians, 
patients and dispensaries) may be seen as a benefit in regards to providing physician education, 
assuring the appropriateness of cannabis products for patients, and mandating dispensary safety 
measures, pharmacy consultations, and quality regulation of medications; the bureaucratic 
slowness of the process and extra steps were regarded as barriers. These barriers highlight New 
York State as being behind the science and actively depriving patients of potentially beneficial 
medication. In-depth interviewing has several limitations. This study has several limitations. First, the 
results are shaped by the questions asked and influenced by social norms and the participants’ 
perceptions of what they think the interviewer wants to hear. Further, the personal nature of the 
data obtained makes it difficult to replicate findings or to extrapolate generalizable results. 
Conclusions: Although New York State’s Program suggests an otherwise simple 
straightforward process toward patient receipt of medical cannabis, stakeholders that were 
interviewed perceive it is overly medically restricted, fear divulging personal and professional 
information to government offices, high cost, and lack of available insurance coverage. 
However, there is a perception of safety compared to opioids or the medications that are 
presently used to combat addiction: Public health policy guiding New York State’s Medical 
Marijuana Program needs to be addressed in a comprehensive manner to reduce barriers to 
prescription, cost, stigmatization, and privacy concerns. Socioecological and biopsychological 
frameworks may be useful in addressing public and legislative policies associated with the 






Introduction   
 Political ideology, conflicting medical evidence and opinions and media attention have 
all affected the formulation of public health policy of medical cannabis. However, the US Drug 
Enforcement Administration (DEA) continues to list medical cannabis as a Schedule 1 agent 
without medical use adds to the difficulty of states’ legislators to implement regulations 
governing the dispensation of registered medical cannabis by credentialed health care providers 
to patients with certified needs (1-3).  The states have regulated medical cannabis differently 
concerning the permissible amount an individual can possess. There are also differences in the 
pathways for provider, dispensary and patient registration and certification to be eligible for 
participation, as are perceptions in its legitimate use that add to the complexity in forming a 
unified public health policy surrounding CBM.    
The past several decades have witnessed a dramatic increase in societal interest in not 
only preventing due to contracting chronic diseases, but in recognizing the importance of social 
influences on health and disease. By targeting social and environmental factors, and 
interventions directed at changing interpersonal, organizational, community, and public policy, 
socio-ecological models have become pivotal in understanding the contribution of society, 
community, interpersonal and intrapersonal factors in disease prevention and health promotion. 
First noted by McLelroy and colleagues (4), the socioecological framework (SEF) model, which 
is in fact a victim-blameless approach to disease according to Tesh and colleagues (5), resonates 
well with health policy measures associated with medical cannabis because it sets aside 
stigmatization. The implementation of public policy by a system-change approach alone, 
according to McLeroy and colleagues (4) is unlikely to succeed in a democratic and pluralistic 
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society because it relies on the consent of the governed, failing to take into account the social 
causation of illness, and its departure from individuals and their choices.   
Qualitative research methods employing semi-structured, in-depth interviews, have been 
employed in a socioecological framework and in biopsychological models to help formulate 
public health policy in medical cannabis (6) and in improving therapeutic decision making in 
adolescent and adult cancer therapy  (7, 8) and mitigating chronic pain (9). Among 649 subjects 
aged 18 to 34 years, identified through Facebook ads targeting tobacco and marijuana users, 
investigators (6) noted that more frequent use of marijuana and greater user friends led to 
enhanced motives and less concerns about driving under its influence (R-squared = 0.442). The 
authors (6) concluded that interventions and campaigns addressing social norms and risk 
perceptions of marijuana use would be successful. 
Lamonica and colleagues (10) investigated the process of new policy implementation of 
medical cannabis in Massachusetts in 2012, when that state legalized medical marijuana under 
Chapter 369 of the Act of the Humanitarian Use of Medical Marijuana statute. They analyzed 
qualitative data generated from ethnographic field notes, media reports, public records, and 
conducted in-depth interviews with medical marijuana dispensary stakeholders, health care 
professionals, and patient consumers, and triangulated their findings with a grounded theory 
approach. The investigators (10), noted gaps in transparency, communication, and education in 
the transition from illegal to legal status under the Massachusetts statute that governed the 
regulations for patients and caregivers, and permitted certification of physicians and the 
registration of marijuana dispensary entrepreneurs. Even after the passage of the statute, and 
while public policy was being developed and implemented, the task of social reconstruction of 
marijuana as medicine (11), was necessary illustrating the social challenges associated with an 
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illegal drug becoming a legal medicine.  Social reconstruction theory, as described by Boeri and 
Lamonica (11) proposes that most of which passes for knowledge in society is socially 
constructed, particularly common sense knowledge that constitutes the reality of everyday life 
for most of its ordinary citizens. This has reformed our concepts of marijuana use from early 
depictions of illicit mindful behaviors (12) to a more modern view of the intricate 
interdependency of social, environmental, and individual biological determinants.         
  The experience in New York State (NYS) has not been formally studied. In 2016, the 
Commissioner of Health of the NYS Department of Health (DOH) certified its Medical 
Marijuana Program and delineated rules for registration and certification and prohibitions 
associated with health practitioners and facilities, and approved its use for managing the pain and 
suffering associated with severe debilitating or life-threatening cancer. Additional regulations 
passed in 2017, amending Section 502, Subpart 55-2 of Title 10 of the Public Health Law (PHL), 
allowed for the sale of medical marijuana products, providing for an improved experience for 
patients and visitors at dispensing facilities, and new courses for prospective practitioners to 
complete their training in a shorter amount of time were mandated. There were new forms of 
medical marijuana available and improving the dispensing facility experience. Under the new 
regulations, registered organizations were allowed to manufacture and distribute additional 
products including topical lotions, ointments and patches, as well as solid and semi-solid 
products including chewable and effervescent tablets and lozenges. Certain non-smokable forms 
of ground plant material were permissible for manufacture and distribution. All products were to 
be subject to rigorous testing and the DOH reserved the right to exclude inappropriate products 
or those, which pose a threat to the public. In improving the dispensing facility experience, the 
new regulations allowed prospective patients and practitioners to speak directly with a registered 
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organization representative, learn about products, and get information about the medical 
marijuana program. In addition, these measures will allow people other than designated 
caregivers to accompany certified patients to the dispensing facility. In refining the training 
program for practitioners, the new regulations allowed for a shortened two-hour version of the 
present four-hour practitioner's course required to certify patients for medical marijuana.  
Other regulatory actions made a number of changes to help enhance the medical 
marijuana program including a broadening of the capability of registered dispensaries to 
advertise, streamlining the manufacturing requirements for medical marijuana products, 
amending security requirements, and clarifying laboratory-testing methods, among other actions. 
Five such dispensaries were authorized to manufacture and dispense medical marijuana in NYS 
to improve patient access, product pricing and availability and the geographic distribution of 
dispensing facilities across the state.  As of August 2017, there were 26,561 certified patients and 
1,155 registered health practitioners (HP) participating in the program. The number of certified 
patients increased by 11,569 (77%) since the addition of chronic pain in late March 2017. 
 
Methods  
 Approval by the City University of New York (CUNY) School of Public Health (SPH) 
Human Research Protection Program was granted to carry out a pilot study examining New York 
State’s “Program,” from a convenience sample of subjects recruited by Vireo Health from whom 
primary data was collected through via in-depth semi-structured interviews and demographic 
questions. The interview instrument employed as shown in Appendix 1 was modified from an 
earlier study (6). Each participant gave verbal consent to participate and each interview was no 
longer than one hour. A topic guide instrument was developed with major domains of 
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stakeholders’ personal views, community norms, attitudes, and behaviors, prescribing practices, 
knowledge of drug cost, insurance coverage, and financial subsidies, pharmacy and dispensing 
processes of medical marijuana (“cannabis”). Dedoose®, a cross-platform on-line application for 
analysis of qualitative and mixed methods research, was used for data analysis. Creating the 
codebook was a reiterative process. The process of making notes about themes immediately after 
completing each interview was followed by a review of contemporaneous notes, which were 
grouped together as similar themes. Then, an initial codebook was compiled from the coding of 
transcripts. After completing the first round of coding, another read through of the transcripts 
was performed to identify narrative sections that were not captured. A review of the data analysis 
outputs resulting from this initial coding was used to identify additional new codes and subthemes. 
The new codebook was entered into Dedoose and the transcripts were reviewed using the updated 
codebook and additional coding added to comply with the new codebook and definitions. Categorization 




 The study cohort included 12 subjects from various locations generally within the 5 
boroughs of New York City (NYC), as well as other areas of NYS, of whom 7 were female, 4 
were male, and one participant declined to specify; 4 subjects were pharmacists, 4 were 
prescribing providers, 2 were patients, 1 was a patient care coordinator, and 1 was a Medical 
Marijuana Educator. All were associated with Vireo Health located in Greater NY and elsewhere 
in NYS. We also gathered information regarding ethnicity, education, employment, age, and 
political identity, however trends were not contextualized using this data.  




 Several different themes emerged overall and within three distinct areas of the implementation 
process for the application and registration process for opening dispensaries, the registration process for a 
referring provider, and the registration of qualifying patients. 
The codes that emerged most frequently overall were “Effective” and “Safe” as 
facilitators, and “Stigma” as a barrier. The code “Effective” was used when participants were 
speaking about the effectiveness of medical marijuana as a medication for various conditions and 
how this has been a facilitator for its legalization, acceptance, and use. The code “Safe” was used 
to identify areas where participants spoke about the demonstrated safety of marijuana as a 
medication, which has shown to be much safer than other legal drugs, including being used to 
help patients come off opioids. It was also used to highlight areas where participants noted that 
legalized versions or the drug are even safer because they are regulated. The code “Stigma” was 
used to highlight areas when participants discussed misperceptions or personal stigmas as a 
barrier to legalization, acceptance, and use. It was also of interest to note that many of the 
participants that extolled the virtues, effectiveness, and safety of the drug, described those they 
personally would be uncomfortable asking for or becoming a medical marijuana patient. 
 
 
Application and Registration Process for Opening Dispensaries 
Themes in both barriers and facilitators to the process for opening dispensaries emerged 
from the interviews. Barriers to the process included “Process,” which identified the very 
rigorous and competitive state process for applying, registering, and running a dispensary. The 
second theme that arose was “Cost,” which included the high amount of capital needed to apply, 
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followed by the high overhead needed to continuously meet all the regulations, coupled with the 
relatively low revenue. These barriers have resulted in low numbers of dispensary companies and 
limited dispensary locations. They have also made the sustainability of the dispensaries as a 
business challenging. 
There were also some themes that emerged as facilitators for the application and 
registration of dispensaries. One such facilitator was actually the regulations themselves. While 
the process and cost were seen as barriers to actually opening dispensaries, the various 
regulations regarding safety measures and dispensary rules of operation were seen as facilitators 
for community acceptance. The regulations that emerged as helpful ranged from the safety 
measures and video surveillance that may actually make the surrounding community safer, to 
regulations about products available, which do not smell or lend themselves to people hanging 
around smoking. A second theme noted as a facilitator for opening dispensaries was job creation. 
A number of participants notes that one of the benefits of the opening of dispensaries around NY 
would be the jobs that it created in those communities. Joe Dolce noted that this trend is being 
seen nationwide, with the number of people working in the cannabis field already surpassing 
other ubiquitous fields, such as bakers. 
 
Registration Process for a Referring Provider  
 Once again, the intensive process was noted as a barrier. This barrier includes the process 
of becoming a referring provider and the extra hoops that providers have to go through after they 
are registered in order to create a referral for each patient. This process generally included 
gaining approval from the place you are employed, taking the class, passing the test, sending 
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paperwork to the state, getting registered, learning the recommendation system, opening a 
website or telling patients about the options, and then going through the prescribing process with 
each patient each time. A second barrier was the education regarding medical marijuana for 
providers. Becoming registered requires a 2-hour course be taken; this is reduced from the 4-
hour course that used to be required. While the reduction in hours does reduce the time 
investment needed for a provider to become registered, it was mentioned by many that it was 
insufficient. It was also noted that the education on cannabis in Medical School and the available 
resources and studies online are also lacking.  
 A few strong themes emerged as facilitators for registration of providers. This included 
new research and personal experiences of patients showing the use of medical marijuana for 
treating a number of complaints and conditions more effectively that the current standard of care, 
as well as, interesting providers in going through the registration process and being willing to go 
through the extra hoops necessary to recommend patients for this treatment. Another motivating 
factor for providers is the safety profile of medical marijuana. Many of our participants noted the 
minimal side effects compared to current standard drugs. They also highlighted the opioid 
epidemic and the potential to save lives with a painkiller with a higher safety profile. While 
neither of these facilitators helped facilitate the actual process, they were seen to facilitate the 
number of providers becoming registered by increasing motivation and interest.  
 
Registration Process for Qualifying Patients  
 This study also examined barriers associated with the registration of qualifying patients. 
A major barrier noted by all the stakeholders was the process from the patient side, such as 
finding a registered provider, bringing documentation of their qualifying condition, having a 
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NYS resident ID, registering on the state website, waiting for the card, having a consultation 
with a pharmacist. It is quite a bit more effort than patients have to put in for other medications. 
Another major barrier is cost. As a federally illegal substance, insurance companies do not 
currently cover the cost of the medication, putting the medication out of reach for a large number 
of patients that could potentially benefit. Another barrier that emerged was stigma. Patients may 
themselves carry stigma towards the drug or may be concerned that others will judge them for 
using the medication. Even among our participants who spoke strongly against the stigma 
surrounding medical marijuana, they noted that they would be hesitant themselves to register for 
a card. Some listed the reason as wanting to promote legitimacy, some indicated that the fact that 
it was still federally illegal or that they didn’t know if their medical boards would like it made 
them hesitant, and a few seemed to realize during the interview that they were in their own words 
“hypocrites” regarding the stigma. The study also highlighted some facilitators associated with 
the registration of qualifying patients. One of the facilitators for registration of patients that came 
up frequently was legalization itself. The very act of legalizing means that patients are more 
likely to consider medical marijuana as a medication. Another big facilitator for patients 
becoming registered is education, both the growing understanding of how effective this 
medication can be and education about the process for registering. This can be from personal 
experience, shared stories of other patients, reports coming out, providers talking about it, but the 
more patients hear and learn about the possibilities, and the more they are educated on the 







 The co-occurrence of themes also highlighted important interactions, for example, co-
occurrence was highest for the codes “Safe x Effective.” Both of these were seen as facilitators 
for the program, the fact that there is now an option for a relatively effective medication for a 
variety of conditions that has a much higher safety profile than many standard of care 
medications is a strong support for the program. The next most frequently co-occurring themes 
were “Limited Qualifying Conditions” as a barrier to the program and “Effectiveness” of the 
medication for many conditions as a facilitator. This tension highlights the theme that arose in 
our interviews that New York is being slow to expand the uses of medical marijuana, which may 
be doing a severe disservice to patients that could potentially benefit. “Stigma” as a barrier for 
use frequently co-occurred with “Education” as a need or as a facilitator for the program, 
suggesting that education is the best way to combat stigma and support the program. “Federal 
Legalization” was a barrier frequently co-occurred with “Cost” as a barrier, which highlights the 
problematic aspects of making medical marijuana legal, and therefore available, in the state of 





 The themes that emerged from the interviews highlight tensions in the Program. While 
tightly regulating the process of certification for all stakeholders (physicians, patients and 
dispensaries) may be seen as a benefit in regards to providing physician education, assuring the 
appropriateness of cannabis products for patients, and mandating dispensary safety measures, 
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pharmacy consultations, and quality regulation of medications; the bureaucratic slowness of the 
process and extra steps were regarded as barriers. These barriers highlight New York State as 
being behind the science and actively depriving patients of potentially beneficial medication. 
These often-mentioned barriers included the onerous registration process for providers and 
patients; overly lengthy (10,000-page) application for the dispensaries, and limits placed by New 
York State on the number of dispensaries and approved diagnosis. 
Although New York State’s Program suggests an otherwise simple straightforward 
process toward patient receipt of medical cannabis (Figure 9), stakeholders that were interviewed 
suggested otherwise.  
Yes, you have to go and do the classes and pass the test, and then send your paperwork to 
the state and wait for the approval by the state, and then get registered, and then they’ll figure 
the health commerce system. And then start prescribing and open up a website, or tell your 
patients what’s going on and convince them that they need it and it’s available to them, and it 
will work. And it’s better than everything else. So there’s a lot of hurdles there. Lots and lots and 
lots of hurdles (Daley, Physician). 
So, it took me until the end of last year to go through the hoops at my work and get them 
to give me the okay to get certified and be able to prescribe for our patients. I do feel like my 
education in marijuana itself is pretty sorely lacking, and even the required course that I took 
was pretty minimal in terms of the amount of information that was available to me, the amount of 
information that it was required for me to have in order to prescribe. Even the sources out there 
for additional information, just prescribing wise whether it’s a side effect profile, or what 
populations would benefit most from it, I still have kind of yet to really feel like I have a good 
amount of knowledge on the subject. (Anne, Physician).  
 
Pertinent views of the limitation of access to medical cannabis in New York State were 
voiced by other interviewees, including its use in a restricted number of medical condition, 
divulging professional information to government offices, high cost, lack of available insurance 
coverage, notwithstanding its safety compared to opioids or the medications that are presently 
used to combat addiction:  
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I know that it is effective with certain conditions. I know that there are many conditions 
out there that it is not approved for. And I have seen some really remarkable results with the use 
of medical marijuana for sick patients (Lydia, Physician). 
So why do they need to create an account with the Health Commerce System at all? Why 
can’t we do that as prescribers since we’re doing that for basically everything else? I can order 
chemotherapy for somebody and they don’t have to do a thing, but for medical marijuana they 
do. There’s a huge step that involves patients, which for every other drug they don’t have to do 
that. So I would take away that involvement, because I feel like that’s really limiting people’s 
ability to get the medication they need. (Anne, Physician). 
Doctors have a new option for pain management and I think that the way that our minds 
are changing about opioids, this is going to be a much more useful option and a much more not 
only useful option but, for one, it's a safer option. You know we should have fewer opioid deaths 
(JC, Pharmacist). 
It’s difficult because I’m on disability. So, I only have a limited amount of income. It’s 
hard when you have to choose between medication and another necessity of the house because 
insurance doesn’t cover medicinal marijuana. So, I don’t understand how the government would 
love to pay for opioids to keep me as a zombie, but not my cannabis that makes me productive. I 
can’t grasp that idea. (Starr, Patient).  
I think, once again, it’s a negative opinion about it. “Oh, you have cannabis, you’re 
using medical marijuana.” It’s like, “Oh, we want to avoid it.” And that’s how I think the whole 
medical community is in general. We don’t have enough providers giving it. We have more 
providers giving Suboxone and the Buprenorphine, and writing opiates than we do have 
cannabis. And that shows you right there. In fact, it should be the opposite way. Cannabis should 
be first and opiates should be last. But nope, it’s the opposite, so ... We’re all stuck with it. 
 
The socioecologic framework model that places society and health policy at the highest 
level, notably stakeholders in policy development, dissemination, enforcement, evaluation and 
revision; followed by community factors below, and interpersonal relationships and intrapersonal 
factors below appears to be useful in assessing medical marijuana programs state-wide and 
probably nationwide. At the societal level, decriminalization remains the greatest obstacle to 
destigmatizing medical cannabis. Legalization at the national level should be continued because 
it has the potential to reduce barriers posed by high cost and lack of insurance coverage. There is 
a need for an expansion of qualifying conditions for medical cannabis, and expansion in the 
number of dispensaries. At the community, level of physicians, pharmacists, and entrepreneurs 
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there needs to be not only effective education and destigmatization of medical cannabis, but also 
supportive networks for sharing information, consistency in prescribing, and the development of 
evidence-based algorithms adjusted to diverse patient populations and applicable products. At 
the intrapersonal and interpersonal level, qualitative ethnographic studies incorporating the views 
of individuals have the potential to provide valuable insights into the lives of patients and their 
friends, caregivers and family members. Education that needs to be available and easily 
accessible on the uses and effects of medical cannabis marijuana, the location of dispensaries and 
their regulations, needs to be racially and historically sensitive, and destigmatizing of its uses, 
prescribers, and dispensers.   
Although there is no published experience in the biopsychological approach to guide 
medical cannabis public policy (13), this approach, which posits that illness and health are the 
result of an interaction between biological, psychological, and social factors, has a role to inform 
Program public health policy.  At a time when healthcare systems designed around acute 
biomedical care models are struggling to improve patient-reported outcomes and reduce 
healthcare costs, the biopsychological approach should be integrated with the socioecological 
framework.  
Despite the many strengths of structured, in-depth interviewing, this modality has some 
significant weaknesses and limitations in regards to design, implementation, and analysis (14). 
First, in-depth interviewing can be difficult. Designing, preparing for, and conducting interviews 
take a lot of thought and skill, and as the interviewer is not only the researcher, but also the tool 
of data collection, it is important that they have the necessary skills to obtain meaningful data. 
Second, data gained during in-depth interviewing may seem overly subjective. However, this 
generally reflects the underlying study design, interviewing technique, and data analysis. The 
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design of the interview and topic guides are shaped by the questions asked. Third, the responses 
are influenced by social norms concerning what can, and should be spoken, and what the 
participant thinks the interviewer wants to hear, as well as their perceptions and opinions are at 
the time of the interview. Lastingly the personal nature of the data obtained makes it difficult to 
replicate findings or to extrapolate generalizable results.  
A significant weakness of the study design was the heterogeneity introduced by the 
involvement of more than one medical cannabis dispensary, which led to a greater geographic 
diversity of subjects; and we did not contextualize demographic data to ascertain trends. The 
latter may be useful to carry out in future studies.    
 
Conclusions  
Viewed through the lens of the real-time perspectives of dispensary entrepreneurs, health 
care professionals, and patients, it is possible to clarify the actors and social and environmental 
factors, and gaps in health policy relevant to the success of New York State’s Medical Marijuana 
Program. With an increasing proportion of healthcare resources devoted to chronic disorders and 
the accompanying need to improve patient outcomes, a biopsychological approach should be 
integrated into future Program policies guiding medical cannabis for the diverse chronic illness 
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Chapter 3:  A Cost Effectiveness Analysis of the Treatment of Sickle Cell Disease-
Related Neuropathic Pain with Medical Cannabis  
 
Abstract 
Background: Opioid analgesic drugs have the propensity for both abuse and medicinal 
use. These drugs have fueled the opioid epidemic, posing a significant public health burden for 
patients who are addicted to, and develop tolerance to them. Despite their serious side effects, 
including tolerance and addiction, opioids remain the standard of care for treating chronic pain in 
patients with sickle cell disease. Medical cannabis provides analgesia through its action on 
endocannabinoid receptors in the nervous system and may serve as an effective means of 
managing chronic pain by mitigating the side effects associated with opioid treatment. We 
sought to evaluate the cost-effectiveness of treating chronic pain in sickle cell disease patients 
with medical cannabis compared to opioids alone. 
Objective: To evaluate the cost effectiveness of adding medical cannabis to opioid 
analgesic medication in the management of chronic pain in patients with sickle cell disease  
between crises. 
Methods: A cost-effectiveness analysis was performed using a decision tree in TreeAge 
Pro to simulate the cost and clinical outcomes of adding medical cannabis treatment for chronic 
sickle cell disease pain compared to the standard of care using opioid analgesic medication 
alone. Probabilities, costs, and quality of life utility weights associated with opioid use and 
chronic pain among patients treated with medical cannabis versus standard of care are derived 
from published literature. Primary outcomes included medication costs and health-related quality 
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of life (measured in adjusted life years, QALYs). The analysis was carried out from a healthcare 
sector perspective with a time horizon of one year. Medication costs associated with chronic pain 
treatment involving cannabis and opioids expressed in 2017 US dollars. Incremental cost-
effectiveness ratios were calculated by comparing cannabis-assisted treatment with opioid-only 
standard of care. One-way sensitivity analyses and threshold analyses were performed to assess 
parameter uncertainty. 
Results: Cannabis-assisted treatment is estimated to reduce addiction by 11.5% among 
SCD patients previously addicted to opioids and improve chronic pain control from 56% to 76%. 
On average, cannabis-assisted treatment increased monthly pain management medication costs 
by $1781.21 per person compared to opioid analgesic treatment alone ($6037.61 vs. $4,256.40) 
and produced 0.06 more QALYs per person (0.58 vs. 0.52 QALYs). The resulting incremental 
cost-effectiveness ratio was $27,219.78/QALY gained. Based on a commonly used 
$100,000/QALY willingness-to-pay threshold, cannabis-assisted treatment was very cost-
effective compared to the opioid-only strategy. Sensitivity analyses suggested that these results 
were robust against a wide range of parameter values. 
 Conclusion: The use of medical cannabis for chronic pain management in patients with 
sickle cell disease is likely to be a cost-effective intervention when compared to the current 
standard of care of opioid analgesics alone. With the increasing availability of medical cannabis 
from dispensaries to treat chronic pain, it may be advantageous to integrate medical cannabis 







Opioid analgesic drugs, often referred to as “opioids” or “narcotics” with the propensity 
for both abuse and medicinal use, have fueled the acronym “opioid epidemic”, posing a 
significant public health burden (1).  According to the United Nations Office on Drugs and 
Crime (2), an estimated 3% to 6% of the world’s population aged 15 to 64 years, or 
approximately 250 million persons, consumed an illicit drug in the past year. According to the 
National Survey on Drug Use and Health (3), of the 22.6 million persons in the United States 
aged 12 years or more who used illicit drugs in 2012, 22.5% used opioid analgesic drugs, lagging 
behind marijuana. Early opioid prescribing patterns are associated with long-term use. While 
patient characteristics are important, clinicians have the greatest control over initial 
prescribing.(3). Patients who may divert or abuse them complicate the long-term prescribing of 
opioid analgesic drugs.  
One particular disorder, sickle cell disease (SCD) is characterized by painful vaso-
occlusive crises and is largely managed with opioid analgesic drugs to date (4, 5). Pain in SCD 
patients between and during crises (6) severely affects individuals' quality of life (QoL). 
Nonetheless, many healthcare providers are reluctant to prescribe opioid analgesic medication 
for SCD patients, citing concerns around the credibility of self-reported pain, and the risk for 
physical dependence, tolerance, and addiction. These concerns are similar to other clinical 
situations involving chronic, non-malignant pain (7). Adults who self-medicate with marijuana 
appear to derive the beneficial effects of the endocannabinoid system on opioid receptors to 
mitigate pain (8) supporting the potential role of medical cannabis in the multidisciplinary 
management of SCD pain. One qualitative study of adults living with SCD found that marijuana 
was the commonest non-opioid pharmacologic approach used in conjunction with opioids (9).  
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There has not been a formal cost effectiveness analyses (CEA) on the use of medical cannabis in 
conjunction with opioid analgesics in SCD pain management.  
As a disease typified by both acute and chronic pain, SCD provides relevant examples for 
exploring the challenge of balancing the burden of patients suffering from pain with the risks of 
opioid dependence and abuse. An estimated 100,000 individuals have SCD in the United States, 
with 2,000 new cases detected annually through newborn screenings (10). Affected individuals 
have atypical hemoglobin molecules that obstruct vessels leading to painful vaso-occlusive crises 
(VOC) in the bones, lungs, brain, kidneys and spleen tissues. Self-reported pain in SCD between 
and during crises severely compromises individuals’ quality of life (QoL). Advancements in the 
science and treatment of this disease have transformed SCD from a childhood illness, to a 
chronic disease of adulthood. Across the age span there can be a more complex pain syndrome 
caused by dysfunction of the nervous system due to underlying neuropathic mechanisms (11).     
Opioid analgesics are used to both treat acute pain crises and to manage chronic pain.   
However, patients who experience severe chronic pain are typically prescribed higher baseline 
doses of opioid analgesic medications, which results in increased tolerance to opioids. Such 
practice blunts the analgesic response of opioids making acute painful crises even more difficult 
to manage. Higher baseline opioid dose for chronic pain management correlates with high levels 
of emergency room (ER) utilization and poor pain control of acute pain crises (12). Further, 
high-dose opioids are associated with the risk of overdose.  Several patient characteristics 
associated with an elevated risk of opioid overdose include a history thereof, and addiction to 
any substance (but particularly alcohol, benzodiazepines, and opioids). The presence of renal or 
hepatic dysfunction also increases the risk of overdose, since the clearance of opioid drugs is 
impaired in patients with either of these conditions, which leads to higher and longer-lasting drug 
56 
 
levels in the blood. Finally, because some cases of overdose may be purposeful suicide attempts, 
a history of suicidal thoughts or attempts and a diagnosis of major depression also increase the 
risk of overdose. 
The opioid epidemic and stigma related to opioid use contribute to an under treatment of 
SCD pain. Research has found negative attitudes towards patients with SCD by health care 
providers reluctant to prescribe opioid analgesic drugs (7). Pain experienced by SCD patients 
remains largely undertreated, in part due to disparities in analgesic administration by healthcare 
providers. The Pain in Sickle Cell Epidemiology Study found that adults self-reported pain in 
54% of the days surveyed (13), making daily pain a constant worry among SCD patients.  
Beyond individual suffering, the management of SCD complications represents major healthcare 
utilization and accounts for a disproportionate amount of medical costs. For example, by age 45, 
a patient with SCD will likely accrue $900,000 in undiscounted medical expenses, and use an 
excess of inpatient and outpatient hospital services, especially ER use for pain management.  
In SCD, the trend of declining QALYs begins in childhood. Young adults with chronic 
pain who are physically and psychologically debilitated present healthcare providers with the 
challenge to implement complex medication regimens by reducing opioid analgesic pain 
requirements, leading to the reliance on emergency room (ER) rather than ambulatory center 
care. Coupling the lack of evidence for optimal chronic pain management in SCD with a 
majority of patients prescribed opioids who may not abuse or misuse them; there remains a 
critical need for better pain management options. This is evident in the challenge to manage the 
complicated pain profiles of SCD patients, their impact on health service usage and reduced QoL 
of life.  
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This study addresses the cost effectiveness of adding medical cannabis to the 
pharmacologic regimen of oral opioid analgesic medication in the management of chronic pain 
in SCD patients between crises. 
  
Methods 
A decision analysis was conducted to estimate the costs and clinical outcomes of two 
SCD pain management strategies: (1) incorporating medical cannabis and (2) standard of care 
with opioid analgesic treatment alone. The decision tree included the prevalence of opioid 
addiction (20% among SCD patients), the probability of reducing opioid dose among SCD 
patients with opioid addiction (11% when supplemented with cannabis), and the various degrees 
of achieving adequate control under the two strategies (76% under combination therapy vs. 56% 
under standard care). These base case assumptions and the sources of data inputs are summarized 
in Table 1. 
Outcome: The main clinical outcome measure is the expected value of quality-adjusted 
life year (QALY) derived from health-related quality of life (HRQoL), which refers to the way 
an illness affects one’s ability to live pain-free, work productively, and interact with family. It is 
expressed as a”utility weight”, a number between zero and 1, with 1 representing perfect health, 
0 typically representing death, and those with disabling chronic disease a fraction thereof (14).  
QUALY expresses the proportion of time lived in perfect health, and is calculated by multiplying 
HRQoL by the number of years of remaining lifespan.  Addiction and chronic pain diminish self-
reported overall HRQoL in SCD (15).  In SCD, the trend of declining HRQoL begins in 
childhood and continues through adulthood (12). Based on self-reported effects of body pain on 
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physical functioning, behavior, general health, and self-esteem, mean HRQoL scores among 
SCD patients were comparable to those newly treated for cancer and rheumatoid arthritis (16).   
Model Structure and Probabilities: The decision analytic model compared the expected 
cost and clinical outcomes of two chronic pain management strategies: Cannabis assisted 
treatment and Opioid-only Standard of Care. The decision tree, as depicted in Figure 1, 
represented six possible health outcome states: (1) sustained chronic pain and no opioid 
addiction; (2) sustained chronic pain and opioid addiction; (3) Opioid-controlled chronic pain 
and no opioid addiction; (4) Opioid-controlled chronic pained and opioid addiction; (5) 
Cannabis-controlled chronic pain and no opioid addiction; and (6) Cannabis-controlled chronic 
pain and opioid addiction .Each health state was assigned a HRQoL utility value, as well as 
estimated annual medication costs based on the best available literature searched in PubMed 
(Table 1). The model was constructed and analyzed using TreeAge Pro 2018.  
Analysis: The analysis was performed from a healthcare sector perspective. The analysis 
time horizon was one year. Medication costs associated with SCD chronic pain treatment 
involving cannabis and opioids were assessed within the decision model and expressed in 2017 
US$. Medication costs were collected from a metropolitan New York City medical cannabis 
dispensary (Vireo Health) and the literature. Given the one-year time horizon, no discount rate 
was applied. The healthcare perspective of the analyses was limited to medication costs. Other 
SCD management costs unrelated to pain control were assumed to be the same under the two 
strategies compared (hence omitted in the incremental cost-effectiveness analysis). Model input 
parameters were derived from published literature and summarized in Table 1. 
The incremental cost-effectiveness ratio (ICER) was calculated by dividing the 
incremental cost of medication by the incremental gain in QALY derived from cannabis-assisted 
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treatment, compared with standard care. The resulting “base case” ICER was compared to 
commonly used willingness-to-pay thresholds (i.e, in the US, $100K per QALY gained). One-
way sensitivity analyses were performed to assess the impact of uncertainty around each input 
parameters on the base case conclusion. In these analyses, the model recalculated ICER by 
varying one parameter at a time across a range of plausible values (Table 2). Plausible values 
were based on the literature and my clinical judgement. For selected parameters with no value 
within the plausible range that altered the cost-effectiveness result (i.e., making a cost-effective 
strategy in the base case not cost-effective), additional threshold analyses were performed to 
determine the parameter value necessary to alter the base case conclusion (17). 
 
Results 
 Among SCD patients addicted to opioids at baseline (20% of all SCD patients), 11.5% of 
them were expected to reduce opioid use, which represented a net 2.3% reduction in the 
population suffering from opioid addiction (or 23 out of 1000 SCD patients). In addition, 
cannabis-assisted treatment was estimated to result in a greater proportion of patients achieving 
adequate chronic pain control. For every 1000 patients, cannabis-assisted treatment was expected 
to result in 200 fewer patients suffering from uncontrolled chronic pain (as a result of increasing 
adequate control from 56% under standard care to 76% under cannabis-assisted treatment). The 
cost of adding medical cannabis to the pain management regimen would incur $242 per patient 
per month, but the strategy reduced the cost of opioid treatment from $354.7 to $241 per month, 
except for those who remained addicted to high-dose opioids. Overall, the cannabis-assisted 
treatment strategy was associated with an incremental cost of $1781.21 per person a year 
compared to the standard of care of opioid analgesic treatment alone ($6037.61 vs. $4,256.40).  
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Largely because of higher HRQoL among SCD patients with adequately controlled pain, the 
cannabis-assisted treatment strategy also produced an average of 0.06 more QALYs per person 
(0.58 vs. 0.52 QALYs). The resulting incremental cost-effectiveness ratio (ICER) was 
$27,219.78/QALY gained, substantially lower than the commonly used $100,000/QALY 
willingness to pay threshold. According to these results, the cannabis-assisted treatment strategy 
was considered very cost-effective compared to the opioid-only strategy (Table 2).  
         In sensitivity analyses, the model was robust across plausible ranges. At a willingness-to-
pay threshold of $100K/QALY, the model outcome was sensitive to the health utility of reduced 
pain for cannabis and opioid treatments. Opioid treatment would be more cost effective than 
cannabis-assisted treatment when the utility of chronic pain under its control decreased from the 
baseline of 0.65 to 0.59, or if opioid treatment increased the health utility of chronic pain on 
treatment to 0.69 from the baseline of 0.60. In threshold analyses performed over a wide range 
against a willingness-to-pay threshold of $100K/QALY, cannabis-assisted treatment would no 
longer be cost-effective when the probability of responding to cannabis treatment was reduced to 
0.48 from 0.76, or when the cost of medical cannabis treatment increased from $242 to $639 per 
month. Sensitivity analyses are shown in Table 3 for key input parameters.  
 
Discussion  
This analysis demonstrates that the use of medical cannabis for the treatment of chronic 
pain in patients with SCD is likely to be a cost-saving intervention when compared to the current 
standard of care of using opioid analgesics to treat chronic pain. As epidemics require a 
paradigm shift in thinking about all possible solutions, the rapidly changing sociopolitical 
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marijuana landscape provides a foundation for the therapeutic development of medicinal 
cannabinoid formulations to address the current opioid abuse crisis in the United States and in 
particular in opioid-dependent patients with SCD (18). There are gaps in understanding the types 
of pain in SCD patients, how it changes over the life course, and the best practices for optimal 
management. Moreover, the mechanisms of acute and chronic pain in SCD patients are poorly 
understood making management of pain a complex issue. While this lack of knowledge impedes 
progress toward novel treatments and management tools, our study nonetheless provides 
rationale for the use of medical cannabis to reduce cost and increase HRQoL in SCD patients. 
This is consistent with the experience of interventional management strategies in SCD that show 
up to a 37% decrease in intravenous opioid use (p = 0.02) and 10% decrease in oral opioid use (p 
= 0.04) among high-utilizing adults with SCD when multifaceted strategies for pain management 
are employed (19).  
The only published CEA (20) addressing the use of medical cannabis in the treatment of 
neuropathic pain in the US marketplace used a Markov model comparing conventional therapies 
for painful diabetic neuropathy modified to include arms for augmenting first-line, second-line 
(if first-line failed), or third-line (if first- and second-line failed) therapies with smoked cannabis. 
Microsimulation of 1,000,000 patients compared the cost (2017 U.S. dollars) and effectiveness 
(QALYs) of usual care with and without adjunctive cannabis using a composite of third party 
and out-of-pocket costs. Model efficacy inputs for cannabis were adapted from clinical trial data. 
Adverse event rates were derived from a prospective study of cannabis for chronic noncancerous 
pain and applied to probability inputs for conventional therapies. Cannabis cost was derived from 
retail market pricing. Parameter uncertainty was addressed with one-way and probabilistic 
sensitivity analysis.  Adding cannabis to first-line therapy was incrementally less effective and 
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costlier than adding cannabis to second-line and third-line therapies. Third-line adjunctive 
cannabis was subject to extended dominance, that is, the second-line strategy was more effective 
with a more favorable incremental cost-effectiveness ratio of $48,594 per QALY gained, and 
therefore, third-line adjunctive cannabis was not as cost-effective. At a modest willingness-to-
pay threshold of $100,000/QALY gained, second-line adjunctive cannabis was the strategy most 
likely to be cost-effective. However, a limitation of that study was the limited scope of published 
clinical trials, as in SCD-related pain, of pain of cannabis, so the authors derived cannabis 
efficacy parameters from participants with human immunodeficiency virus (HIV) neuropathy. 
There was evidence in the literature to suggest that this is a reasonable extrapolation: pain relief 
from standard therapy agents is similar in HIV neuropathy and painful diabetic neuropathy, 
treatment guidelines for both recommend standard therapy agents as first- or second-line agents, 
and short-term effects of cannabis for diabetic pain are consistent with effects observed in trials 
on HIV neuropathy (21).   
 This study had the notable strength of applying the CEA comparing medical cannabis to 
opioid medication for which the latter is medically and socially acceptable across the age 
spectrum and carefully monitored by prescribing physicians. In that regard, there is a reduced 
potential for abuse.     
This study had three notable limitations. First, the analyses did not include financial costs 
associated with non-chronic pain SCD-related healthcare costs, or healthcare costs of opioid 
overdose and addiction treatment.  
Second, the analyses did not include potential societal costs associated with opioid 
addiction including productivity loss and costs incurred in the criminal justice system. The 
inclusion of these costs would likely have further improved the favorable cost-effectiveness of 
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medical cannabis treatment. However, this would have to be balanced with other societal costs 
imposed by cannabis such as impaired driving, presenteeism, or the possibly of marijuana being 
a gateway to use of other illicit drugs. Although most people have opportunities to try marijuana 
even before they have the opportunity to use harder drugs, it is not necessary to postulate 
causality since use of both substances could be a manifestation of the same personality trait. 
Third, the effectiveness of medical cannabis treatment for chronic pain in patients with 
SCD was not available, thus the effectiveness of medical cannabis on other types of chronic pain 
(i.e. diabetic neuropathy) was used as a surrogate, which may not be representative of its true 
effectiveness in SCD patients. However, as further studies are performed in the study of chronic 
pain in SCD, the sensitivity analyses in this study can be used to estimate whether medical 
cannabis treatment is sufficiently effective to be cost-effective. 
Conclusion  
         Medical cannabis provides cost savings and HRQoL benefits in patients with SCD who 
are already taking the standard of care employing opioid analgesic medications for pain relief.  
With legalization of marijuana-derived pharmaceuticals for medical use, there is an opportunity 
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Figure 1A, B. Decision tree for analyzing the cost-effectiveness of cannabis-assisted treatment 
vs. opioid-only standard care. The decision trees depict two chronic pain management strategies 
for patients with sickle cell disease (SCD): cannabis-assisted treatment (“Cannabis”) vs. opioid-
only standard of care (“Opioid only”). At baseline, 20% of SCD patients suffer from opioid 
addiction. Among these patients, 11.46% (“pReduce”) reduce their opioid use cannabis-assisted 
treatment and lower their monthly prescription cost associated with opioids (from cRx_Addict, 
$354.7, to cRx_LessOp, $241). The average monthly cost of cannabis (cRx_can) is $242. 
Regardless of addiction status, cannabis-assisted treatment increases the probability of achieving 
adequate chronic pain control (“Reduced chronic pain”, pPainreduced) to 76%, compared to 56% 
in the opioid-only arm. The HRQoL weights associated with each outcome depends on the 
presence of persistent chronic pain (uChronic Pain vs. uPainreduced) and addiction to opioid 
(uAddicted_dec, expressed as a decrement).   
Notations: □Decision node (strategies compared); ○ Chance node (probabilistic events); 





Figure 2.  Two-way sensitivity analysis: Utility of reduced pain with cannabis-assisted treatment 
vs. opioids. The graph demonstrates how the cost-effectiveness result depends on the values of 
the utility of reduced chronic pain with cannabis-assisted treatment (uPainreduced_can) and the 
utility of reduced chronic pain with opioid-only treatment (uPainreduced_op). Generally, 
cannabis-assisted treatment is more cost-effective when the quality of life (utility) of reduced 
chronic pain under cannabis is higher while the corresponding utility under opioid is lower. 
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Figure 1A. Model Structure.         
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Figure 1B. Model structure with probabilities and expected outcome values.                                                                                     
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Figure 2. Two-way sensitivity analysis: Utility of reduced pain with cannabis-assisted treatment vs. opioids.  
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    Table 1. Model Inputs  
 
Input Value Reference 
Probabilities   
Percent of SCD population addicted to 
opiates 
20% 22  
Probability that chronic pain is reduced by 
cannabis 
0.76 23 
Probability that chronic pain is reduced by 
opioids 
0.56 24 
Probability that addiction is reduced by 
cannabis 
0.1146 25 
Probability that addiction is reduced by 
opioids 
0 Assumption 
HRQoL weight/Utility   
Decrement from opioid addiction 0.15 25 
Chronic pain from SCD 0.48 23 
Cannabis-controlled chronic pain 0.65 23 
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 Opioid-controlled chronic pain 0.60 26 
 Costs (2017 $US)     
Monthly cannabis prescription cost $242 27 
Monthly opioid prescription cost-opioids 
only 
$354.70 28 
Monthly opioid prescription cost under 
reduced opioid dose when supplemented 
with cannabis 
$241   28 
 
Abbreviations: SCD, sickle cell disease; US, United States; $, dollars. 
 
 
Table 2. Cost Effectiveness Analysis Result 













$4,256.40 0.52 - - - 
Cannabis 
Treatment 
$6037.61 0.58 $1781.21 0.07 $27,220 
 
Abbreviations: QALYs, quality adjusted life years, ICER, incremental cost-effectiveness ratios. 
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                                      Table 3.Sensitivity Analysis                                        74 
Input Range Outcome (threshold 
$100k/QALY 
gained) 
Value needed to 
change outcome 
(even if outside of 
plausible range) 
% of population 
addicted 
0 to 100 Does not change Not possible 
Probability of reduced 
addiction with cannabis 
0 to 0.25 Does not change Not possible 
Probability of 
responding to cannabis 
treatment 




0.4 to 0.8 Does not change 0.96 
Cost of cannabis 
(monthly) 
$25 to $500 Does not change $639 
Cost of opioids 
(monthly) 
$25 to $500 Does not change Not possible 
Utility decrement of 
addiction 
0 to 0.5 Does not change Not possible 
Utility of reduced pain 
with cannabis-assisted 
treatment 





   
Utility of reduced pain 
with opioid-only 
treatment 
0.5 to 0.8 Threshold exists 0.69 




Chapter 4: The Analgesic Benefits of Medical Cannabis for Cancer-Related 
Neuropathic Pain    
Abstract  
Background: Cannabis-based medications have been employed to reduce physician and 
patient reliance on opioid pharmacotherapy for neuropathic pain. One particular condition that is 
a legitimate use of medical cannabis is cancer-related neuropathic pain both as an effective 
treatment to diminish the need for opioid use.   
Objective: To study the usefulness of cannabis-based medication as an alternative or 
adjunctive agent to traditional opioid analgesic pharmacotherapy in the management of cancer-
related neuropathic pain in a pilot group of patients residing in an upstate community of New 
York State subserved by a single medical marijuana dispensary.  
Methods: Twenty subjects with cancer-related neuropathic pain from a single medical 
cannabis dispensary in upstate New York met eligibility criteria for study inclusion: age 18 years 
or older, English speaking, and cancer-related neuropathic pain to engage in in-depth interviews 
of their lived experiences with cannabis-based and opioids analgesic pharmacotherapy in a cross-
sectional observational cohort study. The dispensary pharmacist recorded demographic data, 
dosages and costs of these two medications. The coronavirus disease 2019 outbreak prompted 
premature conclusion of data collection.  The level of pain at entry was ascertained using a 
computed score based on the average of graded interference with enjoyment and general 
activities, and a visual analog scale, respectively scored none to worst (0 to 10, and 0 to 5).          
Results: There 8 men and 12 women of mean age 59.5 years with cancer-related 
neuropathic pain. All 20 subjects were assigned a cannabis-based medication in the form of oral 
(7 subjects), sublingual (2 subjects), inhaled (4 subjects) products alone, or in combination (7 
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77subjects). Opioids were taken at entry in 16 subjects. The level of neuropathic pain was 
ascertained at entry in 7 subjects as 5.7 via graded interference with enjoyment and general 
activities, and 4.25 via the visual analog scale. The employment status was known in 18 subjects, 
14 of whom were not working due to disease disability (8 subjects) or retirement (6 subjects) 
while 4 others were working full-time (3 subjects) or part-time (1 subject).  Subjects live with 
pain and discomfort that ultimately affects their quality of life.  
Emergent themes relate to experiences of cancer and its treatment, perceptions and 
experiences of pain management strategies, perceived benefits of medical cannabis, enablers of 
improved pain management, and barriers to pain management. Results highlighted the widely 
variable experiences with cancer, cancer treatments, pain management strategies, and their 
impact on pain levels and quality of life both between and within individual experiences. 
Benefits of using cannabis-based medication in addition to, or as a replacement for, opioid 
medicines included the improved safety profile of cannabis-based medication, the improved 
flexibility and control subjects had for managing their variable pain, and the reduced dependency 
on opioids and other medications. Reported enablers of improved pain management strategies 
included the moral, financial and logistical support of family, friends and employers, health 
providers that were knowledgeable about cannabis-based medication, and personal exposure and 
awareness about cannabis-based medication. The major barriers highlighted challenges resulting 
from the lack of full integration into the current health systems such as inconsistent guidance and 
access, and financial costs. 
Discussion: Cannabis-based medications are effective pharmacotherapy in the treatment 
of cancer-related neuropathic pain and useful adjuncts in tapering or reducing the need for opioid 
pharmacotherapy with much fewer side effects.  
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Conclusion: Cannabis-based medications played an essential role in the management of 
cancer-related neuropathic pain in a small cross-sectional cohort both as an alternative and 
adjunctive agent to traditional opioid analgesic pharmacotherapy. Future randomized control 
studies are needed to confirm the efficacy of cannabis-based medications in the treatment of 
cancer-related neuropathic pain and as an adjunctive agent to reduce reliance on opioid analgesic 
medications.        
 
Introduction  
 There is an urgency to integrate CBM into the multidisciplinary approach to pain 
especially cancer-related neuropathic pain.   Cancer pain results from inflammation, mechanical 
invasion of bone or other pain-sensitive structures, and nerve injury. It is severe, persistent, and 
often refractory to treatment with opioid-based medications or “opioids.”  It is one of the most 
common symptoms in cancer patients, especially in advanced disease. It occurs in a significant 
proportion of patients during diagnostic and therapeutic procedures, and in some, pain may be 
the first symptom of cancer. The causes of pain in cancer patients are often multifactorial 
including direct and indirect cancer effects, anticancer therapy and co-morbidities. Moreover, 
pain in cancer patients has mixed pathophysiology including both nociceptive and neuropathic 
components, especially in patients with bone metastases. Recognition of pain and its appropriate 
assessment and treatment may significantly improve patients and families' quality of life (QoL) 
(1, 2).   
The proposed research sought to ascertain the usefulness of cannabis-based medication 
(CBM) as an alternative or adjunctive agent to traditional opioid analgesic pharmacotherapy in 
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the management of cancer-related neuropathic pain in a pilot group of patients subserved by a 
single medical marijuana dispensary in upstate New York.   
 
Methods  
 This study was granted ethical clearance by the University Integrated Institutional 
Review Board in accordance with the City University of New York Human Research Protection 
Program (CUNY HRPP) procedures. Data collection was conducted between January and March 
2020. 
Study Design: This cross-sectional observational cohort study was designed to document 
the lived experiences and management of cancer-related neuropathic pain employing CBM in a 
convenience sample of 20 subjects served by a single upstate Vireo Health marijuana dispensary 
in Binghamton, New York via in-depth semi-structured phone interviews. De-identified, 
routinely collected demographic and quantitative data including cannabis and opioid-based 
medications and other analgesic medication was shared by the dispensary.   
Design of Research Tools: A topic guide of key themes was developed focusing on the 
experience of cancer and its treatment, perceptions and experiences of pain management 
strategies, perceived benefits of medical cannabis, enablers of improved pain management, and 
barriers to pain management, and formed the basis for the design of the semi-structured, in-depth 
interview tool, allowing for the interviews to be largely patient driven while ensuring that the key 
themes were addressed in each interview. Specific probes were reviewed and refined during the 
study in an iterative process. The interview instrument is shown in Appendix 2.  
Scoring Pain: Subjects were electively scored for pain intensity at registration at the 
dispensary using a computed score based on the average of graded interference with enjoyment 
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and general activities (PEG) scale scored none to worst (0 to 10); and a visual analog scale 
(VAS) shown in Appendix 3. The PEG score was calculated from the sum of averages of pain 
intensity (P), interference with enjoyment of life (E) and interference with general activity (G). 
The VAS was an ordinal facial recognition scale scored none to worst (0 to 5).  
Study Site: Data was collected from among clients of the Upstate medical dispensary that 
provides pharmaceuticals and follows the needs of clients referred by a physician. The research 
site was chosen in collaboration with Vireo for two primary reasons; 1) the area was identified as 
an under-researched location with no previous research studies having been conducted here, and 
2) the availability of a sizable and receptive population of eligible clients accessing this 
dispensary.  
Participants and Recruitment: Study participants were selected using purposive, non-
probability sampling. Vireo clients and caregivers of clients with cancer diagnoses attending the 
Upstate dispensary meeting the following criteria were eligible to participate: 1.) age >= 21 
years; 2.) English speaking; 3.) under care of a referring pain management provider; 4.) not 
currently pregnant or breast-feeding. The investigator (DSY) for enrolment in the study 
contacted participants who met the eligibility requirements were recruited by the lead pharmacist 
at the dispensary, and, after giving permission. In total, 20 participants were included in the 
study.  
  Consent: As the study was conducted over the phone, oral consent was obtained from all 
participants prior to commencing with the data collection. A full explanation of the study, 
participation, confidentiality and risks was provided to participants. Participants were asked to 
provide consent for both the audio recording of the phone interview and for participation in the 
research. Oral consent was asked for again after the audio recording device was turned on to 
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have a recording of given consent. The contact details for CUNY HRRP were provided to each 
participant and copies of the consent form were made available for participants upon request. 
Participants were advised that they would not suffer any adverse consequences in their 
relationship to Vireo Health if they decided to withdraw from the study. 
Data Management: Participant names were not used during the interviews and audio files 
of each interview are stored with strong, ZIP-compatible Advanced Encryption Standard (AES) 
password protected devices under a participant ID number. Identifying data was removed during 
the transcription process and soft copies of the transcripts were saved under participant ID 
numbers on a password-protected device. De-identified quantitative data were stored on a 
password-protected device. All data will be retained for three years after the study and then 
destroyed.   
Analysis: The analysis of the qualitative data was conducted using thematic analysis. 
Dominant themes emerging from the interview were identified through systematic review. 
Salient concepts were coded, and their occurrence and recurrence labelled by hand using 
Microsoft Word. Coded excerpts were copied into a themes matrix in Excel where emerging 
trends were critically analyzed according to the study aims. 
 
Results 
Subject Characteristics: Table 1 lists the characteristics of the 20 study subjects. There 8 
men and 12 woman of mean age 59.5 years with cancer-related neuropathic pain associated with 
lymphoproliferative tumors (acute myeloid leukemia, Waldenstrom macroglobulinemia, multiple 
myeloma, and lymphocytic lymphoma), and malignant cancer of the breast, lung, ovary, prostate, 
gallbladder, and skin. Two patients each with lung or prostate cancer had an earlier breast cancer. 
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The tumor type was not available in 2 subjects. All 20 subjects were assigned a CBM including 
in the form of oral (7 subjects), sublingual (2 subjects), inhaled (4 subjects), or in combination (7 
subjects). Opioids were taken at entry in 16 subjects. The level of neuropathic pain was 
ascertained at entry in 7 subjects with a mean PEG and VAS score of 5.7/10 and 4.25/5 
consistent with severe neuropathic pain. The employment status was known in 18 subjects, 14 of 
whom were not working due to disease disability (8 subjects) or retirement (6 subjects) while 4 
others were working full-time (3 subjects) or part-time (1 subject).   
 
Emergent Themes  
Experiences of cancer and treatment 
 Subjects live with pain and discomfort that ultimately affects their QoL. Participants 
described a range of cancer and treatment experiences, from quick and straightforward 
procedures that left them cancer free, to complex, life-long battles with the effects of both cancer 
and the treatments. Pain and discomfort not only ranged from minimal to excruciating but 
included many forms of pain from dull aches, locked up muscles, acute stabbing sensations, bone 
pain, nerve damage, restless limbs, heaviness, stomach pain, neuropathy, etc. The types and 
intensity of pain not only varied between patients but also within patient experiences. As one 
participant explained: 
This week was a good week, and then the next week comes around and all of a sudden, 
you’ve got three or four new things you’ve got to deal with (Subject 5).  
 
Changing patterns of symptoms and pain was a common theme among subjects 




The sources of subjects’ pain and discomfort also varied. While many of the participants 
described feeling no symptoms from the cancer itself, seven indicated that the cancer and the 
effects of the cancer in their body caused pain. Fourteen of the study participants described pain 
and discomfort resulting from the treatments they were on for the cancer including 
chemotherapy, forms of radiation, surgeries, and various injections. The responses to the various 
forms of treatment varied significantly between participants. For example, among those 
undertaking some form of chemotherapy, subject experiences ranged from minimal impact to 
side effects so severe that the chemotherapy treatments had to be halted. As one participant 
related: 
They were going to have me do chemo the whole summer, but they said no, because it 
affected me so bad. I said I don't want to do this. If it's going to kill me before the cancer does 
(Subject 8). 
 
The effect that cancer and cancer management has on participants lives is manifold, 
affecting participants’ mental health, work, social lives, and ability to perform daily tasks. Study 
subjects described intensive routines with multiple visits to various health centers and doctors’ 
offices per week. They navigated advice, sometimes conflicting, from multiple different doctors 
and specialists comprising their health care team. Managing this schedule, particularly when 
feeling ill or in pain, is frequently described among participants as stressful in and of itself. This 
is particularly true when some of those visits for treatment are known to be the source of 
additional pain and discomfort as evident in the comment: 
I was always trying to manage everything, and I still had a lot of nausea. It was making 
things very stressful for me. To the effect where I would be extremely scared about three days 




Beyond this, the uncertainty regarding outcomes and ability to mitigate and manage 
symptoms created additional anxiety and depression. The pain itself was described as a source of 
anxiety and depression: 
 I felt depressed because I thought I was going to die. I felt sad I was leaving my 
grandkids. It wasn’t depression, it was just like ‘aw shit, now I gotta die.’ And then you think, 
‘well, I’m pretty old anyway.’ I felt like that during the times when it hurt so much and I would 
be in bed just in pain and thinking ‘well, maybe it’s better to die.’ And then when I started 
feeling well, I was happy again. Happy I could do things and that the pain was gone (Subject 6). 
 
At a time when patients are facing high levels of anxiety, their physical condition also 
disrupts their normal support structures in routines. Work is a huge aspect of many people’s lives 
and that was reflected in the discussions about the ways in which cancer had impacted the 
subject's quality of life. While six of the research participants were retired at the time of the 
study, eight participants were on disability resulting from their health and treatments. Of those 
still working, all describe challenges and absences related to their condition.  
The loss of work also contributes to the social impact of cancer in these individuals' lives. 
As one subject noted: 
Actually a lot of my coworkers have been some of my best friends. You go to the job every 
day and you see the same people (Subject 13).  
 
Beyond this, participants spoke frequently of the ways in which their social life was 
restricted because of their compromised immune systems. This was particularly challenging for 
participants with children attending school and for grandparents wanting to watch and spend 
time with their grandchildren while they still had time.  
Additionally, participants described losses of parts of their identity and support 
structures, such as continuing to pursue their passions and hobbies or attend social gatherings or 
religious functions. The physical constraints and experiences of the disease and the treatments 
further impact even daily basic activities of participants such as driving, cleaning, cooking, 
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dressing and even getting out of bed in the morning. Participants describe difficulties fulfilling 
obligations to their family and having to ‘push through’ and ‘pay for it’ in pain to get things 
done. All participants described impacts on their daily routines, but the worst were related to 
limitations due to pain. As one subject described: 
When I get the pain, the tiredness and nausea, when it hits, you can’t do anything. You’re 
in bed, you’re moaning, it just hurts so much (Subject 6). 
 
Perceptions and experiences of pain management strategies 
In attempting to manage their pain and symptoms, participants describe the varying ways 
that they are guided by health providers, self-guided research, and family and friends. The 
majority of the participants explained that their doctors and pain management teams typically 
recommended a prescription for an opioid as the first line option for pain management. Their 
health care providers provided recommendations for the use of medical marijuana for pain and 
symptom management to less than half the participants. Some of the subjects hypothesized that 
this was because their health provider was not certified to register them for a medical marijuana 
card and/or lacked knowledge about the uses of medical marijuana. Of those that did receive 
recommendations for medical marijuana from their providers, the majority were in cases in 
which the opioids had not provided adequate pain relief or as a recommendation for improving 
sleep, appetite, or treating anxiety.  
Many of the subjects reported being the ones to initiate discussions with their health 
providers regarding the potential benefits of medical marijuana. The responses of the health 




We brought it up to our oncologist and they didn’t even advise us where to go. They just 
said well, you know, we don’t really know a whole lot about it, studies have been done. We 
would suggest some Percocet, some Vicodin. (Subject 1).  
The majority of the research participants described some level of self-driven research 
contributing to their decision to incorporate medical marijuana into their care routine. As one 
subject stated: 
I have to do it myself. There’s research involved. That was my struggle. But if you get the 
right team together, that’s the best way to manage the pain. And I think I did that. And I’m super 
happy I have a medical marijuana card. It’s been a lifesaver so far (Subject 4).  
 
Five of the participants described advice from friends and family as being the major 
deciding factors for convincing them to incorporate medical marijuana into their management 
regime. In recounting the advice from friends and family, participants often emphasize how 
knowledgeable these people were about the current research on both medical marijuana and 
cancer. 
 Study participants also had varying experiences and perceptions of the process they had 
to go through for their pain management strategies. Most agreed that they had straightforward 
access to their opioid prescriptions through their pain management doctor, although a few noted 
that the increased regulations imposed in recent years had made the process more challenging. 
As one participant stated: 
I know before this opioid crisis started, my doctor give out my pain medication to me. We 
had no problems. We managed the pains right. Just like I'm doing now with the pain specialist. 




Participants also noted that they have to let their doctor know monthly when they are out 
of their opioids, as they are not allowed to have refills and it must be called in each month. For 
medical marijuana, participants noted that it was possible to get a few months’ supply at one 
time. However, the process of getting and maintaining a medical marijuana card was variable. 
Some participants had to pay a three hundred dollar fee for their medical marijuana card while 
others said they got theirs free. This discrepancy did not correlate with income or insurance type 
but may have had to do with the policies in place at the time that they applied for their card. 
Some subjects reported that their doctor pushed the application through and they were registered 
quite quickly, while others described stumbling through the process with minimal guidance and 
support and waiting weeks to get their card. One participant describes his navigation of the 
process: 
That was hard, as far as how to get everything, because it's a process. First you got to get 
the appointment with the specialist and then, he's got to do his paperwork. If you pay a copay. 
Then you got to go online and you got to do this and then they send you a temporary license and 
then you got to make an appointment with the dispensary and all that stuff. So not knowing all 
that process was kind of tough. I mean, I have done it, it's fine, but a lot of little steps. Which I 
know it could be easier. Probably just easier to get your opioid medications (Subject 13).  
 
Many participants describe the process as a lot to navigate when you are already ill and 
managing all the other aspects of your cancer and treatments. 
 Access to medical marijuana also emerged as a salient theme in participants’ experiences 
of cancer pain management, particularly in terms of distance to dispensaries, access to their pain 
management regime while in hospital, and access to illicit forms of marijuana. While a few 
participants noted that they had some challenges with physically accessing their opioid pain 
medication (for example if they were going out of state), most described their access to opioids 
as a fairly simple matter of filling a prescription at the local pharmacy, or sending someone to 
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pick it up on their behalf. Access to medical marijuana was much more variable between 
subjects. Dispensaries were local and convenient for only three of the research participants. The 
remaining subjects reported the nearest dispensary between forty-five minutes to two hours from 
them. Further, participants had varying perceptions and experiences on getting a caregiver card 
to allow someone to pick the medical marijuana up on their behalf if they could not make the trip 
themselves.  
Lived experiences of access to pain management while in hospital also varied. Two 
participants who had used medical marijuana to replace opioids in their pain management 
strategy described hospital experiences where they did not have access to any form of pain 
medication as follows: 
If they could prescribe medical marijuana, I would have been fine. I told them it's not that 
I want a narcotic, it's that it's acute pain (Subject 18).  
 
One participant ended up in hospital for five weeks without access to medical marijuana, 
which was the only thing he had found to be effective for his neuropathy. From his hospital bed, 
he petitioned the hospital and reported: 
It took me over a month to get them to change their rules to get the medical marijuana 
allowed to be taken there. I had to change the policies of the hospital which took me about five 
weeks I think, to change their policies and it was a tough fight (Subject 9). 
 
Due to the additional processes for gaining access to medical marijuana, a number of 
participants described accessing illicit forms of marijuana first to determine if it provided them 
with any benefits before going to the effort of obtaining it legally. Two study subjects even 
stated that their doctor recommended they go this route. Some participants were able to access 
regulated forms of marijuana while visiting other states or obtain it from someone with a medical 
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marijuana card. Others obtained unregulated forms through friends or family members or by 
‘knowing a guy’. However, a few participants described experiences that highlight the potential 
negative impacts of lacking guidance and dosage recommendations during an initial trial 
experience.  
All participants with a wide range of experiences discussed the effectiveness of opioids 
and medical marijuana for treating pain and other symptoms that affect an individual’s quality of 
life. Opioids were spoken of only in terms of managing pain and inflammation, whereas medical 
marijuana was spoken of in terms of management of pain, neuropathy, mental health, sleep, 
appetite, and muscle relaxation. As one patient expressed: 
The marijuana pill, it takes care of more than one issue. It gets me out of the depression, 
it helps me to want to get up and do things and actually get up and do things, it helps with the 
anxiety and the depression and the pain (Subject 18).  
 
Participants also describe the ways in which the benefits provided by medical marijuana 
for other symptoms also helps them manage their pain. For example, eating and sleeping 
regularly were linked to improved immunity to withstand the cancer and treatments. 
Inflammation and muscle tension can contribute to experiences of pain, so by reducing the 
inflammation and muscle tension in the body, participants experienced longer pain relief 
benefits. Besides physically reducing the tension, some participants also described that the 
impact medical marijuana had on reducing their anxiety helped them face and manage their pain 
better, commenting: 
It takes away my anxiety and it lets me be me for a little bit. If I don't vape, all I think 
about is pain, I can't handle this, I can't take this (Subject 15). 
 
In terms of the effectiveness of opioids and medical marijuana for directly managing the 
pain, respondents reported very individualized experiences. Some described the opioids as doing 
nothing for the pain other than making them comatose, others describe their pain as 
90 
 
unmanageable without opioids. Some participants that did find pain relief from their opioids 
mentioned that the relief only lasted a short amount of time and wore off before their next 
scheduled dose. Participants had similar varying experiences of medical marijuana’s impact on 
their pain. One participant describes his experience: 
The problem I have with marijuana is the marijuana doesn't actually go directly to the 
pain. It goes to your brain (Subject 20).  
 
Others described their experience using medical marijuana as ‘life changing’ or ‘night 
and day’ for managing their pain. When discussing the effectiveness of medical marijuana, the 
majority of subjects also had experiences of needing to adjust their dosage and ratio of THC to 
CBD to find what would address their pain effectively. Participants also discussed variation in 
the effectiveness based on product type. Many subjects described a mixed regime of opioids and 
medical marijuana for effectively managing their pain. 
Subjects also discussed variable experiences with side effects. Side effects associated 
with opioids included nausea, depression (“oxy blues”), lethargy, irritability, feeling high or a 
general ‘terrible’ or ‘yucky’ feeling. Experiences of the side effects differed dramatically 
between participants with some reporting no side effects and others describing themselves as ‘no 
longer functionally human’, ‘gone’, or ‘not themselves’. Managing the sometimes-manifold side 
effects from the opioids led many participants to additional medications such as sleeping pills, 
laxatives, anxiety medication, and nausea medication. Many of these additional medications also 
proved to have side effects. With the complexity and evolving nature of patients' experiences and 
regimes for treating and managing their cancer and associated symptoms, the lived experience 
can become difficult to parse out as mentioned: 
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I seem to have so many side effects, at different times, that I don't know. But then again, 
I'm taking so many different meds. I don't know what's from what you know, I have no idea what 
the side effects (Subject 13). 
 
Side effects associated with medical marijuana included increased appetite, feeling high, 
unfocused, paranoia, and lightheadedness. While there was variation in the side effects 
experienced by study subjects, most reported the side effects to be very mild. Increased appetite, 
the most commonly described side effect, was reported by all but one participant who 
experienced it as a benefit for their condition. As one subject expressed: 
I don’t have any negative side effects with it, other than the munchies. And as far as I’m 
concerned that’s not a negative, not with what I’m dealing with. I’m somehow maintaining my 
weight when I shouldn’t be (Subject 4).  
However, one participant, who had been trying to lose weight, listed this side effect as a 
drawback. Experiences of feeling high also varied, the majority reported that they did not feel 
high from their medical marijuana, while a few described the higher THC dosage products 
hitting them ‘like a ton of bricks’. In those cases, participants described working with the 
pharmacist to find a balance that did not make them feel high. One participant experienced 
severe lightheadedness that she attributed to taking her oil while anesthesia from her surgery was 
still in her system, and another experienced a mild case of paranoia on one product that she tried. 
Another relevant theme that emerged in discussing pain management was the experience 
and perception of stigmas and fears associated with both opioids and medical cannabis. A few of 
the study subjects described experiences of stigmatization from health providers regarding their 
opioid usage. These participants expressed frustration and despair at their pain being treated 
dismissively and at the perception that their health provider thought they were lying. One of the 
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participants in this study describes how confronting it is to be in intense chronic pain and have 
multiple health providers dismiss your attempts to find effective pain relief either through 
opioids or medical marijuana. As she stated,  
They thought that I just wanted opioids because I had addiction and that I was faking it 
and that I just wanted to get high on medical marijuana. That's an awful thing to be told (Subject 
15).  
 
Beyond medical providers being hesitant about the opioid addiction, the majority of 
participants themselves expressed a fear of becoming too dependent. You cannot turn the TV on 
without realizing that billions of people are hooked on oxycodone, as stated by one subject: 
That's my biggest fear. I don't want to go down that road. That's why I thought I would 
find a substitute (Subject 11).  
Four of the study participants refused to take opioids, opting for over the counter options 
or medical marijuana to manage their pain. Many participants had personal experiences with 
friends or family with addictions that contributed to their fear of becoming addicted themselves. 
As one subject noted: 
My big thing with opiates is I’ve seen what it did to my brothers. They’re like full-blown 
junkies and it’s sad (Subject 4).  
 
Beyond addiction, some participants also brought up reservations about the safety profile 
of opioids and the effects of adding those chemicals on top of all the other shocks to the system. 
Many participants struggle with balancing their pain experiences with fear of what opioids are 
doing in their bodies: 
You read stuff about opioids and how they, you know, destroy your body and I get my 
kidneys and my liver checked. I get my blood work done every so often to see how everything's 
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handling because I'm 63. I've been on it since 50. So it's up to god what's going to happen to me. 
You know, I don't know (Subject 15). 
 
While stigma-surrounding opioids is increasing, most participants as decreasing 
described stigma in relation to medical marijuana. However, some study subjects still 
encountered stigma and fear surrounding their use of medical marijuana. One participant 
described hiding his self-medication with medical marijuana from his health providers for fear of 
being stigmatized as a junkie and denied treatment. Another relayed his fears surrounding drug 
testing at his job, as it is still a federally illegal substance. Some perceptions of stigma are more 
subtle and contradictory. One man who prided himself on never participating in drug and alcohol 
culture described the contradictory response of his family when transitioning from opioids that 
made him ‘aggressive’ to a medical marijuana product: 
The only thing I can say is with the medical marijuana my family all wanted me to do it 
and then once I did it, my family all uses it against me, because I'm now a ‘pothead’ or 
something. Everything changed, like the grandkids don't come over anymore. It just kind of hurt 
my feelings (Subject 9). 
 
While all participants proclaimed themselves to have always been pro-legalization of 
medical marijuana and many reported even being pro-recreational legalization as well, this was 
not always apparent in their actions. Many participants described initial resistance to getting their 
medical marijuana card exemplified in the comment: 
I wish I had listened to my husband before that. Because I kind of resisted for a while, I 
said no I don’t want it. It really made a big difference (Subject 17).  
 
Others expressed fear of taking as much as was recommended. The most commonly 
expressed fears around medical marijuana were about uncertainty of how it would affect them, 
using it when they were alone, or using it during the day when they needed to work, drive, or 
care for children. Even participants that said they did not feel side effects from the medical 
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marijuana product expressed these concerns. When asked further about these concerns, most said 
that they had not yet tested it and wanted to be cautious. 
 
Perceived benefits of medical marijuana 
Themes surrounding subjects perceived benefits of adding medical marijuana into their 
management routine included the effectiveness in treating symptoms, the non-addictive nature 
and strong safety profile, the ability to take as needed, the immediate and extended relief, and the 
reduced dependency on opioids and other prescriptions. As described previously, some 
participants described medical marijuana as effectively treating pain or other symptoms that had 
previously been unmanageable with other treatment options. Many participants extolled the 
benefits by describing activities that they had not been able to do for years and now were able to. 
Effectively addressing pain, insomnia, appetite, depression, and anxiety reduced the negative 
impacts on social lives and daily activities and greatly improved quality of life. As one 
participant stated: 
I would go into any oncologist’s office and say ‘get your medical marijuana card, you’ll 
be a human again’ (Subject 5). 
 
Participants also discussed the benefits of medical marijuana in terms of the safety profile 
of the drug and the fact that it is non-addictive. One of the study subjects who had admitted to 
smoking marijuana for the majority of his adult life even before getting his medical marijuana 
card, had actually chosen to quit taking his medical marijuana ‘cold turkey’ after he no longer 
needed it for his treatments. When asked about any withdrawal symptoms he stated that he had 
not experienced a single symptom of withdrawal and felt great. He contrasted that with the 
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withdrawal symptoms he had experienced years prior when he had been on opioids for a short 
time following a knee surgery. Participants described reduced anxiety around addiction when 
using medical marijuana as well. 
The safety profile also allows prescriptions for medical marijuana to be much more 
frequent and flexible than structured opioid regimes. Many study subjects discussed the benefit 
of this for providing them with more control to effectively manage their symptoms.  
The pain pills were helping but it wasn’t really doing anything on a long term, just about 
six hours would be up and I knew it was about to be up because the pain would start immediately 
right back in (Subject 10).  
 
In addition, as noted above, participants often described a lot of variability in their pain 
experiences, with good and bad days. In managing his unpredictable pain, a study subject 
explains: 
It's very random, it’s not like I can take the same thing every day and it's going to work, 
you know? (Subject 13).  
 
The immediate effects of medical marijuana on the system in the comment also bolstered 
the additional sense of control: 
I could take as much as I needed, maybe a puff or so whenever I felt it was coming and 
before it got really bad. It helped me have control over what I took and how often. It was really 
quick also. The effect was not the 20 minutes you have to wait with the pills, it was within a 
minute or so. That also relieved a lot of anxiety because I felt like I am in control and it’s not 
making me drowsy (Subject 17). 
 
A few participants also noted their experience with more extended benefits from taking 
medical marijuana. Many participants noted being woken up by pain or feeling terrible in the 
morning after their nighttime dose of opioids wore off. However, a few study subjects noted that 
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since they started taking medical marijuana at night, their morning symptoms seem to be relieved 
as well. 
Another perceived benefit of adding medical marijuana into the subject’s management 
routine was the reduced dependency on opioids and other medications. Medical marijuana was 
noted as having the potential to reduce opioid dependency for both addicts and for those 
developing a tolerance to their pain management regime. For patients that were maxed out on 
their opioid dosage and still unable to achieve pain control, the addition of medical marijuana 
into their regime provides a much-needed additional source of relief. For patients concerned with 
developing a tolerance or addiction, this option for reduced dependency helps mitigate that 
anxiety. Further, many participants noted that reduced dependency on opioids would also reduce 
their opioid associated side effects and improve their quality of life. One participant described in 
detail the months of suffering through chemotherapy and the opioid induced lethargy and 
depression before switching to medical marijuana, concluding: 
We lived three almost four months of hell. I wish we would have got the [medical 
marijuana] sooner and didn’t have to do the fentanyl patches and the oxycodone, because that 
stuff actually took quality time away (Subject 5).  
 
Additionally, participants noted reductions in their reliance on other medications to treat 
the side effects, including anxiety medications, depression medications, nausea medications, and 
laxatives. A few participants also reported reduced or ended regimes of self-medication as 
follows: 
I was actually drinking very heavily. I got to the point where I could sleep if I was 






Enablers of improved pain management 
Enablers of improved pain management that emerged out of this study include the 
support of family and friends, the support of health providers, the support of employers, and 
exposure and awareness about medical marijuana. Family and friends played an integral role in 
almost every subject’s story. For some, they contributed to awareness and knowledge about pain 
management options as discussed above. For others, they advocated on their behalf to the health 
providers or provided backing for their decisions in the comment:  
There's not a lot of information about this. You have to ask and re-ask. It's great to have 
people in your corner. When you have someone like that, you have another set of ears in there 
with you (Subject 14).  
 
Family and friends also played roles in terms of financial and logistical support, 
providing rides, helping with daily activities and chores, and picking up prescriptions. In terms 
of medical marijuana, family support of the use seems to be pervasive across almost all stories 
and has been an enabler for incorporating it into the individual’s pain management routine. 
Notably, in the one case where the participant described that his family had stopped bringing his 
grandkids around, it had been the same family members that had convinced him to switch to 
medical marijuana and continued to verbally support that decision. 
Another major enabler for improved management emerging from subject reported 
experiences was a trusted and supportive medical team or health provider. Participants that had 
good working relationships with their medical team and described their health providers as 
supportive of their decisions and preferences were frequently the ones that had an easier time 
navigating the process of obtaining their medical marijuana card, were processed more quickly, 
and described their experiences in a more positive way. Even in cases where only one health 
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provider on an individual’s medical team was supportive, it was often enough to expedite the 
process. 
Another enabler for improved management strategies that emerged was exposure and 
awareness of the uses of medical marijuana. Having exposure to people who have had successful 
experiences with medical marijuana raised subjects’ awareness and knowledge about the 
potential for it to be a beneficial addition to their own management strategy.  
Knowing people that use medical marijuana or having prior experience themselves also 
contributed to an understanding of what the personal experience and benefits might be. One 
participant explained her experience with medical marijuana as follows: 
My niece has a brain problem. And they put her on it. And I tried it and I liked it. You 
know, I said, it does work (Subject 10).  
 
Exposure to others using medical marijuana was also useful for overcoming fear and 
stigma surrounding medical marijuana as mentioned in a subject’s statement: 
I never had anything against it because I’ve seen what it’s done for my brother. I’ve seen 
people who have cancer who have used it through hospice care (Subject 7).  
 
However, it is worth noting that prior experience with recreational marijuana may act as 
an enabler or a barrier depending on the person. Some subjects mentioned prior experience with 
recreational marijuana and in three of these subjects, this prior experience made them more 
reticent to use medical marijuana. The reasoning was that they did not want to become the 
person they used to be. However, these participants reported that these fears did not materialize 






Barriers to pain management 
When asked about the greatest challenges to the incorporation of medical marijuana into 
management regimes participants almost unanimously identified financial impacts and lack of 
integrated services. Nearly all participants regardless of whether or not they found the cost 
prohibitive mentioned the cost of medical marijuana. As a federally controlled substance, 
medical marijuana is not covered by health insurance, so incorporating it into a pain management 
strategy necessarily causes a financial impact: 
The price is very expensive. It's not cheap and without insurance covering it, it gets very 
expensive. The opioid medication is covered under my insurance (Subject 20).  
 
Some participants described medical marijuana as very expensive but ‘worth it’. For 
others, they spoke about it as a commitment, a choice that you make and budget and sacrifice for. 
Others spoke of the cost as prohibitive; shaping their pain management strategy by what they 
could afford as opposed to what most effectively managed their chronic pain and provided them 
with quality of life. One woman describes an experience that echo many other subjects’ 
experiences: 
I have the green, yellow and red. The red one actually helped me the most, it just came 
down to the cost of it. I just couldn’t afford to go to that one, so I went to the yellow one, because 
it was cheaper (Subject 7). 
 
 In addition to paying for the medical marijuana products themselves, some participants 
also had costs associated with obtaining the medical marijuana card: 
I can still not wrap my head around why it cost us three hundred bucks when we’re 
having all this hardship, all the problems. It cost me three hundred bucks that I had to scrimp 
and scrounge for. I’m not kidding, I literally counted change for that. So, it cost us three hundred 
bucks to get this card, but there is no co-pay at the pharmacy for this oxycontin or fentanyl. How 
does that even make sense? (Subject 5). 
 
A few participants also mentioned indirect costs associated with having to take time off 
work and pay gas to drive an hour and a half to three hours round trip to the nearest dispensary. 
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Especially at a time when subjects are already experiencing income loss, medical expenses, and 
other indirect cost in association with their condition, the monthly and indirect costs of medical 
marijuana can prove to be a substantial barrier that negatively affects peoples’ quality of life. As 
one study respondent expressed: 
I just wish I could afford it more. That’s why I agreed to do this, because it’s a terrible 
thing to have to make people feel there’s no hope for them. They know it’ll help them, they just 
can’t afford it (Subject 7).  
 
A few participants also noted that the cost barrier might drive patients to find cheaper 
options from illicit sources. One participant noted the safety issues already emerging around 
vape pens being sold on the street where the marijuana has been cut with other ingredients.   
         The other barrier for improved management strategies in general, and the incorporation 
of medical marijuana in particular, that emerged in nearly every research participant's story was 
the lack of integrated services. In describing their health management and their medical team, 
study subjects frequently mentioned as many as nine different health providers and specialists 
they were working with. Prescriptions for opioid medications, steroid shots, and medical 
marijuana may all be managed by different doctors with the patient themselves either managing 
the master list of prescriptions or bringing the list with them to share with and update each of 
their various health providers.  
Further, subjects described the wide variation in knowledge or awareness about medical 
marijuana, its uses and potential benefits, and the process for obtaining it among health 
providers. This resulted in knowledge gaps and conflicting or no guidance provided to the 
subjects and contributed to stress and anxiety in trying to manage a serious illness within a 
fractured system. As one participant expressed:  
I guess I was just scared. They need to have a better dialogue for people or something to 
make it more open. If you're not looking for it, there's nothing really that comes after you to get 
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it. There's no information out there that's readily available for you to get medical marijuana 
(Subject 9).  
 
Additionally, inconsistencies within the larger health system create barriers for patients 
who have incorporated medical marijuana into their management routine. Many of these 
participants end up in hospital for extended periods for various reasons as they are dealing with 
serious, and often life threatening, conditions. However, depending on the policies of the 
hospital, patients may be deprived of their medications. One participant highlighted the 
inconsistencies in policy that left him with unmanaged pain while hospitalized explaining:  
Here's the thing, they prescribe medical marijuana for patients there, but they would not 
give medical marijuana on their property to patients (Subject 9).  
 
All the participants in this study agreed that when faced with a debilitating condition, 
services should be integrated to improve access to options for management strategies that can 
have dramatic impacts on a person's quality of life. One participant stated: 
There is a need for more choices, as in the medical marijuana through the hospital, 
through oncology, through the pharmacies, to where you don’t have to go to a specialized place 
for this stuff (Subject 5). 
 
Discussion  
Cannabis-based medication was administered to a cohort of 20 subjects with cancer-
related neuropathic pain at an upstate NY dispensary. Their lived experiences with cancer and 
cancer treatments, their pain management strategies including opioid and cannabis based-
medicines, and factors that enabled or presented barriers to their effective pain management were 
ascertained via in-depth, semi-structured phone interviews. The lived experiences of participants 
with cancer, treatments, and the resultant symptoms and impacts on their quality of life varied 
dramatically, both between subjects and within individual experiences. This included their 
respective management strategies addressing the breadth of cancer-related pain. These 
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observations suggest that cancer-related pain may relate to the type, location, treatment, and 
stage of disease, which is expected to vary among a cohort such as this unselected for any of the 
aforementioned aspects.  
Individual experiences in cancer-related pain and the management of it affected subjects 
differently notwithstanding the similarity in baseline analgesic therapy. Altogether, 80% of 
subjects were taking opioid pharmacotherapy to treat severe neuropathic pain before adding 
CBMs in oral capsule, sublingual tincture, inhaled vaporized forms, or a combination thereof. 
Some of these subjects were failing to achieve effective management with opioids alone, other 
subjects were experiencing effective pain relief but having to manage negative side effects from 
the opioids that they were hoping to mitigate, and still others achieved no noticeable relief from 
the opioids.  
Those subjects who had refused opioid medicines and opted to use CBMs as their first 
line strategy for management of pain and symptoms cited prior experiences with opioids that 
made them unacceptable or undesirable. Cannabis-based medication provided a socially 
accepted, safe and well-tolerated adjunct or alternative to opioids in this cohort. The foremost 
challenge of the cohort was in formulating their own strategy of pain management, combining 
available multimodality aspects. The addition of CBMs to participants management strategies 
not only provided an option that was more effective for some subjects and some types of pain, it 
also improved the flexibility of subjects' pain management strategies providing individuals with 
more control over addressing their own fluctuating pain experiences.  
Further, CBM mitigated a variety of other symptoms common among cancer patients that 
opioid medications do not address and often can exacerbate. These include insomnia, nausea, 
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weight loss, anxiety, and depression. In this way, the inclusion of CBMs into patient pain 
management strategies had knock on effects and was able to reduce not just patient dependency 
on opioid medications, but reduce the number of medications they were taking to treat other 
symptoms. These various lived experiences of cancer and its management highlight the need for 
improved options and adaptability for achieving optimal pain and symptom control. Lack of 
integration proved to be a major barrier for subjects creating and maintaining an effective pain 
management strategy. CBM should be integrated into pain management regimes to ensure that 
patients are consistently provided with knowledge about the range of options available to create 
an individualized strategy that effectively meets their needs, to ensure that they have consistent 
access to the various medications in their strategy, and to ensure it is affordable for them to 
maintain.       
The historical background of CBM provides a useful guidepost to its present role in 
cancer analgesia especially as an adjunct to opioid pharmacotherapy. Nearly a half-century ago 
investigators (3, 4) established the tolerance, efficacy and equivalency of THC compared to 
opioids using single-dose analgesic methods to study the relative efficacy of a 5, 10, 15 and 20 
mg dose of oral THC over a 6-hour period and its benefit compared to placebo in cancer pain. 
There was significantly analgesia compared to placebo especially at 15 mg, which was well 
tolerated despite sedative effects and mild mental clouding. A 10 mg dose of THC was 
comparable in its analgesic effects to 60 mg of codeine with only mild sedation. Such patients 
incidentally had improved mood, sense of well-being, and reduced anxiety. 
Van den Beuken-Van Everdingen and colleagues (5) later performed a meta-analysis of 
the prevalence of cancer pain in published literature from up to 2014, noting that among 122 
studies the prevalence of pain was 39.3% after curative treatment; 55.0% during anticancer 
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treatment; and 66.4% in advanced, metastatic, or terminal disease. Moderate to severe pain (in a 
numerical rating scale score ≥5) was reported by 38.0% of all patients.  The authors concluded 
that despite increased attention on assessment and management, pain was a prevalent symptom 
in cancer. The authors concluded that in the decade ahead, it was incumbent upon physicians to 
develop and implement effective interventions in cancer pain. Hence, the importance of 
integrating medical cannabis into the available modalities of pain management at all stages of 
cancer care. 
Johnson and colleagues (6) reported their experience in the treatment of intractable 
cancer pain employing non-pharmaceutical preparations of whole-plant extract cannabis in a 
study of 177 patients who experienced inadequate analgesia despite chronic opioid dosing. 
Patients were randomized to a tetrahydrocannabinol: cannabidiol (THC: CBD) extract (n = 60), 
THC extract (n = 58), or placebo (n = 59). The primary analysis of change from baseline in mean 
pain. A numerical rating scale score showed statistically significance in favor of THC: CBD 
compared with placebo (improvement of -1.37 vs. -0.69), whereas the THC group showed no 
significant change (-1.01 vs. -0.69). Twice as many patients taking THC: CBD showed a 
reduction of more than 30% from baseline pain NRS score when compared with placebo (23 
[43%] vs. 12 [21%]). Hence, THC: CBD extract was highly efficacious for relief of pain in 
patients with advanced cancer pain not fully relieved by strong opioids.  
This was followed by the first randomized placebo-controlled graded-dose trial  (7) of 
patients with advanced cancer and opioid-refractory pain randomized to low dose (1-4 
sprays/day), medium dose (6-10 sprays/day), or high dose (11-16 sprays/day) nabiximols 
(Nabiximols is the U.S. Adopted Name [USAN] for Sativex® [GW Pharma Ltd, Wiltshire, U.K 
) or placebo. Among 263 subjects who completed questionnaires of their QoL and mood and an 
105 
 
assessment of average daily pain, worst pain and sleep disruption during 5 weeks of treatment 
there was a response rate of 30% responder rate in a primary analysis that did not  differ between 
nabiximols versus placebo (overall P = .59). However, a secondary continuous responder 
analysis of average daily pain from baseline to end of study demonstrated that the proportion of 
patients reporting analgesia was greater for nabiximols than placebo overall (P = .035), and 
specifically in the low-dose (P = .008) and medium-dose (P = .039) groups. In the low-dose 
group, results were similar for mean average pain (P = .006), mean worst pain (P = .011), and 
mean sleep disruption (P = .003). Adverse events were dose-related and only the high-dose group 
compared unfavorably with placebo. This study supported the efficacy and safety of nabiximols 
at the two lower-dose levels and provides important dose information for future trials. 
Although this is the first study conducted in an outpatient community dispensary via in 
depth interviews and supported by pharmaceutical monitoring of dosages to study cancer 
analgesia, a recent analysis of medical cannabis users in a comparable setting may provide useful 
insights. Yau and colleagues (8) recruited 100 medical cannabis users from a community 
dispensary in Vancouver Canada who completed a structured clinical interview including the 
Mini-International Neuropsychiatric Interview, Perceived Stress Scale-10, Patient-Reported 
Outcomes Measurement Information System (PROMIS) Fatigue Scale, PROMIS Sleep 
Disturbance Scale, Beck Depression Inventory, the Patient Health Questionnaire-15 and the 
Brief Pain Inventory. The investigators noted that among this population, 50% met criteria for a 
prior but not current major depressive disorder (MDD), 43% had anxiety disorders, and non-
alcohol substance use dependence and substance use was diagnosed in 42% including drug 
dependence within the past year. When subjects were asked to choose one specific condition as 
their primary reason for using medical cannabis, anxiety (43%) was the most common condition 
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followed by insomnia/sleep issues (18%) and depression (16%). Of note, the small cohort was 
not selected using standard epidemiological techniques, and so extrapolation to the general 
population as a whole may not be valid. However, if the subjects chosen at random are 
representative of at least the types of individuals who use cannabis dispensaries this has 
implications for the present study, there may be implications for the present study.  
One other study examined medical cannabis from a dispensary member’s perspective in 
New England (9) in a sample consisting of patients with chronic pain from a variety of 
overlapping sources including back-pain, arthritis, neuropathic pain, post-surgical pain, 
abdominal pain, and headaches but not cancer who completed an educational intake session 
lasting 45 minutes and a 77-item online survey with forced-choice demographics and medical 
history items and open-ended questions.  In response to "How effective is medical cannabis in 
treating your symptoms or conditions?" with options of 0% "no relief" to 100% "complete 
relief," the average was 74.6% ± 0.6. The average amount spent on MC each year was $3064.47 
± 117.60, median = $2320.23, range = $52.14 to $52,140.00. In this study, open-ended responses 
were coded into themes and subthemes. Analysis of answers to "What is it that you like most 
about medical cannabis (MC)?" (N = 2592 responses) identified 10 themes, including health 
benefits (36.0% of responses, for example, "Changes perception and experience of my chronic 
pain."), the product (14.2%, for example, "Knowing exactly what strain you are getting"), non-
health benefits (14.1%), general considerations (10.3%), and medications (7.1%). Responses (N 
= 1678) to "What is it that you like least about MC?" identified 12 themes, including money 
(28.4%, for example, "The cost is expensive for someone on a fixed income"), effects (21.7%, 
for example, "The effects on my lungs"), the view of others (11.4%), access (8.2%), and method 
of administration (7.1%). The largest positive theme identified, which related to health benefits 
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illustrated how respondents described in great depth how medical cannabis improved their 
treatment of chronic-pain and enhanced their quality of life. The primary negative theme 
identified however was cost, which varied depending on the formulation and the preferred route 
of administration. Medical cannabis, unlike other treatments for pain such as opioid 
pharmacotherapy, is not covered by insurance; so this fiscal finding is unsurprising. These 
findings provide a patient-centered view on the advantages (for example, efficacy in pain 
treatment, reduced use of other medications) and disadvantages (for example, economic and 
stigma) of medical cannabis.   
There are several limitations to this study. First, subjects were prescribed a CBM in the 
ratio of THC: CBD of 1:1 and, depending upon analgesic and side effects, advanced to higher 
proportions of THC: CBD. Pharmacists were generally ignorant of the opioid-doses prescribed 
by their pain management physicians so there was little opportunity to overtly diminish their 
tolerance of opioids or balance the dose of CBM with opioids to improve analgesia. This was 
generally left to the patient with the advice of their pain management physicians often based 
more on individual patient preferences than the collective wisdom of a single guiding medical 
philosophy.      
Second, the cohort was not screened for opioid abuse, substance usage, or psychiatric 
disease that might affect their tolerance and dependence upon cannabis and opioids. Clients who 
visit marijuana dispensaries to obtain medical cannabis for pain appear to be at heightened risk 
for a psychiatric illness with a greater likelihood of abusing cannabis and opioids when they self-
medicate (10). Their choice of the CBM product and route of administration may be different 
that recommended by the pharmacist as for example vaporizing versus capsules in those who 
108 
 
prefer to simulate smoking weed. However, there is no evidence that a given CBM alters 
efficacy or the corresponding dose of opioids.  
Third, subjects also took CBM for reasons unrelated to neuropathic cancer pain to 
manage cancerous symptoms of cancer-related nausea, vomiting, anorexia, weight loss and 
cachexia due to cancer, chemotherapy and radiation therapy to improve QoL (11-14).   
Fourth, the number of subjects was small and the types of cancers varied making it 
difficult to generalize the response to CBM and other analgesics to a single type of cancer. Apart 
from the diversity of cancers surveyed, study subjects were in different stages of their cancer and 
in different phases of their treatment and recovery, all of which could affect the level of pain and 
the root cause such as chemotherapy, surgical, or metastatic spread.   
Fifth, inhaled delivery of cannabis has historically been the preferred method for fast 
action, but the rise in respiratory syndromes associated with vaping (15) has contributed to a 
decline in this route of administration. Moreover, some subjects may feel the stigma of 
vaporization and switch to, or combine it with other preparations even when it has been effective 
and well tolerated. Ultimately, the effectiveness of the given regimen of CBM may have been 
adversely affected.    
Sixth, the decision to taper opioids and continue CBM was implicit in their participation 
but it was not a criterion for their continued inclusion.  
Seventh, Amazon gift cards were given out to subjects at entrance and exit of the study, 
which in those with limited financial means may have incentivized them to participate beyond 
their inherent desire to take CBM or taper off opioids.  
Eight, the emergence of COVID-19 pandemic led the Honorable Andrew Cuomo, 
Governor of NYS to decree a state of emergency on February 24, 2020 for all New Yorkers. 
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While the Vireo Health dispensary was able to continue operating with social distancing 
precautions, those with severe comorbid diseases were encouraged to shelter-in-place and 
communicate remotely. With the increased burden of COVID-19 on its business operation, study 
protocols were cancelled. This precluded a comparative prospective analysis of monthly 
estimated drug costs, efficacy of CBM in allowing a tapering of opioid doses, and a formal CEA 
of the two drug classes. 
Ninth, the level of pain at entry by Vireo Health via PEG and VAS, which was found to 
be severe, was derived from a minority (40%) of subjects. It is unclear why other subjects were 
not scored but if this was an elective process by the dispensary, it suggests at least a bias of 
reporting by those most severely affected and possibly not representative of the cohort.  The 
agreement between PEG and VAS is reported to be excellent (p=0.90, 95% confidence intervals 
[CI] =0.86-0.93). However, both have limitations. Specifically, investigators (16). In contrast, 
investigators (17) find that VAS scores may be skewed by the introduction of a crying face in 
individuals that come from cultures that find crying to be less acceptable or honorable thereby 
under-reporting pain levels. Fear and anxiety may bias pain reporting and interfere with attempts 
to measure intensity. Moreover, the reliability of PEG and VAS reporting may be influenced by 
the performance of practice sessions beforehand that the dispensary did not conduct.  
Lastly, other specific data of ethnicity and educational background, such data if collected, 
could be clues to evaluating or contextualized subjects’ responses in relating to socioeconomic 







 Overall, the present study identified many perceptions and experiences about the 
efficacy, and barriers, to incorporating CBM into pain management strategies for improving pain 
and symptom control and quality of life among patients with cancer-related neuropathic pain. 
Independent of individual providers or their institutions, such views about medical cannabis as 
adjunctive or alternative therapy to opioid-based pharmacotherapy may enhance its role in the 
multimodal approach to chronic pain. Although this study is limited in some ways, it does 
provide a window into the chronic pain patient’s favorable and unfavorable experiences with 
CBM.  It is increasingly apparent that the patient’s perspective is important in the successful 
management of chronic pain. An important next step following up on the results of this research 
is to work collaboratively with Vireo Health to extend the findings, and establish algorithms and 
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Characteristics of Study Participants (N=20) 
                                                                        N. (%) 
Men                                                               8 (40) 
Woman                                                    12 (60) 
Mean age (years)                                          59.5 
Tumor type 
  Lymphoproliferative                                      7 (38)                  
  Breast                                                            3 (16) 
  Lung                                                              2 (11) 
  Ovary                                                             1 (6) 
  Skin                                                                1 (6) 
  Prostate                                                           1 (6) 
  Gallbladder                                                    1 (6) 
  NA                                                                 2 (11)  
Cannabis Product at Entry 
  Oral only                                                        7 (35) 
  Sublingual only                                              2 (10) 
  Inhaled only                                                   4 (20) 
  Combination                                                  7 (35) 
Taking Opioids at Entry                            16 (80) 
Mean Pain Score (n=8) 
  PEG                                                      5.7/10 
  VSEG       4.25/5                                                                           
 Employment 
  Disabled                                                         8 (44) 
  Retired                                                           6 (33) 
  Full-time                                                        3 (17) 
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  Part-time                                                        1 (6) 
  NA  
Abbreviations: PEG, average pain intensity, interference with enjoyment of life (E) and activities 





     Emergent Themes and Subthemes 
Themes Sub-themes 









Management routine Health care visits 
Medical team 
Time management 


















Benefits Non-addictive/safety profile 
Frequency of use 
Extended benefits 
Reduced dependency on other medications 













Chapter 5 - Conclusion  
Introduction  
 Imagine you are sick with a chronic condition that either escapes understanding, such as 
chronic pain, or worse, one for which there is no cure such as cancer. In the best scenario, you 
hope for effective management by your physicians and their pharmaceutical options, yet the 
choices are either limited or the ones you try may make you feel sicker. Consider also that the 
US FDA has little say so in the approval of a medication, acting more as a marketing agent after 
the pharmaceutical industry establishes its safety in clinical trials, and you will find that we have 
not yet started an open dialogue about medical marijuana. This is unfortunate because there is an 
extensive literature about the medical applications for cannabis. A recent book details the 
history, speciation, genetic structure, pharmacology, pharmacokinetics, dosing, administration, 
and safety of cannabinoid agents, and their role in maintaining homeostasis for the body during 
chronic illness (1). This dissertation fills gaps in the present literature showing the reader, the 
medical community, politicians, public health policy makers, and entrepreneurs and the 
emerging marijuana industry, a way forward to harness its potential.     
 
Summary and Relevance of Study Results 
Chapter 2, Aim 1 
Chapter 2 of this dissertation, based on Aim 1, was an analysis of the NYS Medical 
Marijuana Program as seen through the lived experiences of a convenience sample of 12 key 
stakeholders accessing and utilizing the medical marijuana program in New York State through 
Vireo Health, Inc. The study participants, chosen for their willingness to participate in a research 
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protocol without expectation of compensation, all underwent in-depth semi-structured 
interviews. Among them, dispensary entrepreneurs, prescribing physicians, pharmacists, and 
patients filling medical cannabis prescriptions in one or more dispensaries managed by Vireo 
Health in New York. The choice of this study design and the SEF model to understand its public 
policy implications was to capture the present interest in targeting personal, interpersonal, 
organizational, community, and public policy concerns, relevant to disease prevention and health 
promotion.  
Overall, very positive thematic codes that emerged most frequently overall were 
“Effective” and “Safe” as facilitators, and “Stigma” as a barrier.  The code “Effective” was used 
when participants were speaking about the effectiveness of medical marijuana as a medication 
for various conditions and how this has been a facilitator for its legalization, acceptance, and use. 
The code “Safe” was used to identify areas where participants spoke about the demonstrated 
safety of marijuana as a medication, which has shown to be much safer than other legal drugs, 
including being used to help patients come off opioids. It was also used to highlight areas where 
participants noted that legalized versions or the drug is even safer because they are regulated. 
The code “Stigma” was used to highlight areas when participants discussed misperceptions or 
personal stigmas as a barrier to legalization, acceptance, and use. Many subjects extolled the 
virtues, effectiveness, and safety of CBM, but admitted nonetheless that they would be 
uncomfortable asking for or becoming a medical marijuana patient.  
Notwithstanding, there was frank criticism of NYS’ program by many stakeholders 
evident in other codes such as “Process” and excessive “Cost”, by entrepreneurs critical of the 
excessively bureaucratic process of the application and registration process for opening 
dispensaries; among physicians wary of the Program’s educational bureaucratic program of to 
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become certified providers; and finally among clients, who cited difficulty in finding providers, 
assembling documentation, registering on the Program website, waiting for the certification card, 
arranging a pharmacist consultation at the dispensary, as well as perceived stigmas of cannabis, 
and excessive cost.  
 
Chapter 3, Aim 2 
Chapter 3 of this dissertation, based upon Aim 2, was a study of the cost-effectiveness of 
adding medical cannabis to opioid analgesic medication in the management of chronic pain in 
patients with sickle cell disease using a decision tree model analyzed in TreeAge Pro to simulate 
the cost and clinical outcomes.  Probabilities, costs, and quality of life utility weights associated 
with opioid use and chronic pain among patients treated with medical cannabis versus the 
standard-of-care were derived from published literature. Primary outcomes included medication 
costs and health-related quality of life (measured in adjusted life years, QALYs). The analysis 
was carried out from a healthcare sector perspective with a time horizon of one year. Medication 
costs associated with chronic pain treatment involving cannabis and opioids were expressed in 
2017 US$. Incremental cost-effectiveness ratios were calculated by comparing cannabis-assisted 
treatment with opioid-only standard-of-care. One-way sensitivity analyses and threshold analyses 
were performed to assess parameter uncertainty.  Cannabis-assisted treatment is estimated to 
reduce addiction by 11.5% among SCD patients previously addicted to opioids and improve 
chronic pain control from 56% to 76%. On average, cannabis-assisted treatment increased 
monthly pain management medication costs by $1781.21 per person compared to opioid 
analgesic treatment alone ($6037.61 vs. $4,256.40) and produced 0.06 more QALYs per person 
(0.58 vs. 0.52 QALYs). The resulting incremental cost-effectiveness ratio was 
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$27,219.78/QALY gained. Based on a commonly used $100,000/QALY willingness-to-pay 
threshold, cannabis-assisted treatment was very cost-effective compared to the opioid-only 
strategy. Sensitivity analyses suggested that these results were robust against a wide range of 
parameter values.  The use of medical cannabis for chronic pain management in patients with 
sickle cell disease is a cost-effective intervention when compared to the current standard-of-care 
of opioid analgesics alone. With the increasing availability of medical cannabis from 
dispensaries to treat chronic pain, it appears advantageous to integrate medical cannabis into the 
multidisciplinary management of sickle cell disease, and other chronic pain disorders.  
  
Chapter 4, Aim 3 
 Chapter 4 of this dissertation, based upon Aim 3, was an analysis of the NYS Medical 
Marijuana Program seen through the lived experiences of a convenience sample of 20 subjects 
accessing and utilizing the medical marijuana program at a single dispensary in upstate New 
York through Vireo Health. Study subjects who met study entrance criteria were all diagnosed 
with cancer-related neuropathic pain and willing to undergo a qualitative in-depth, semi-
structured interview study of their lived experiences of a cohort of subjects with cancer-related 
neuropathic management in nearly all cases with opioids based medication. The study design 
was to capture personal, interpersonal relationships critical to their care, community dispensary, 
and public policy concerns pertinent to the SEF of Chapter 2, and relevant to their disease and 
health promotion.  
The themes that emerged centered on their lived experiences of cancer and its treatment, 
perceptions and experiences of pain management strategies, perceived benefits of medical 
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cannabis, enablers of improved pain management, and barriers to pain management. This 
population of clients presented experiences and perceptions of living with cancer, treatments of 
cancer, pain management strategies, and impact on their quality of life that varied dramatically 
both between and within individual experiences. Prior to adding CBMs into pain management 
strategies, the majority of participants had been managing pain with opioid-based medications, 
with varying levels of success. Subject’s reasons for altering their pain management strategies 
included failure to achieve any pain control with prescribed opioids, inability to attain sufficient 
pain and symptom control, or experiences of severe side effects. The subjects who pursued CBM 
cited prior experience with opioid-based medications, which made them unacceptable or 
undesirable. Perceived benefits of the incorporation of CBM into pain management strategies 
noted by the subjects included the improved safety profile of CBM, the improved flexibility and 
control subjects had for managing their variable pain, and the reduced dependency on opioids 
and other medications.   
Themes surrounding enablers and barriers for improved pain management strategies 
pointed to challenges resulting from the lack of full integration of CBM into the US and NYS 
health systems, resulting in inconsistent awareness and knowledge about the uses of CBM, 
inconsistent access including policy and logistical barriers, and disjointed processes for obtaining 
pain management medications. In light of this, enablers included exposure to and availability of 
knowledge and guidance around CBM as well as moral, logistical, and financial support 
structures. Major barriers of navigating the system included the heavy and often prohibitive 
financial costs, issues around consistency of accessibility, and lack of guidance.  





There is integration of health policy In NYS in regards to the marijuana industry that is 
evident in the New York State’s Medical Marijuana Program that regulates the operation and 
certification and accessibility of medical cannabis in accordance with the State’s belief that the 
positive effects of a regulated marijuana market outweighs the potential negative impacts to 
society, communities, and individuals, or the view of the FDA that it is an illicit substance 
without medical use. Rather, there are clear medical uses for cannabis as shown in vast RCTs 
and in limited CEAs. Notwithstanding, there are significant barriers to dispensary entrepreneurs, 
prescribing physicians and patients, even when they conform to state-mandated program 
policies. This applies to dispensary ownership, provider and patient certification, and accessing 
cannabis. There is also stigmatization related to the acceptability of medical cannabis for the 
diseases it is approved and deemed cost-effective compared to the standards of care therapy. 
Viewed through the lens of public health and a socioecological framework model, medical 
cannabis policy in NYS needs to be reframed as an alternative to opioid pharmacotherapy in 
serious disorders such as cancer- and sickle cell disease-related neuropathic pain, in which there 
is favorable cost-effectiveness. Local communities and dispensaries can help in this process 
when they express the interdependence of social, environmental and individual biological 
determinants. At the societal level, there must be support for cannabis in the struggle against the 






Implications for Health Policy  
 The past several decades have witnessed a dramatic increase in societal interest in not 
only preventing due to contracting chronic diseases, but in recognizing the importance of social 
influences on health and disease. By targeting social and environmental factors, and 
interventions directed at changing interpersonal, organizational, community, and public policy, 
socio-ecological models have become pivotal in understanding the contribution of society, 
community, interpersonal and intrapersonal factors in disease prevention and health promotion. 
The SEF, which is in fact a victim-blameless approach to disease according to Tesh and 
colleagues (2), resonates well with health policy measures associated with medical cannabis 
because it sets aside stigmatization. The implementation of public policy by a system-change 
approach alone, according to McLeroy and colleagues (3) is unlikely to succeed in a democratic 
and pluralistic society because it relies on the consent of the governed, failing to take into 
account the social causation of illness, and its departure from individuals and their choices.  
Socio-ecological models have proven useful over the decades in assessing public health concerns 
as diverse as child abuse (4) and adolescent sports-related concussion (5).   
Both quantitative and qualitative research methods have been employed in SEF 
analogous models of marijuana use to guide public health policy.  Berg and colleagues (6)  
studied correlates of level of marijuana use and driving among 649 subjects aged 18 to 34 years, 
identified through Facebook ads targeting tobacco and marijuana users noting that more frequent 
use of marijuana and greater user friends led to enhanced motives and less concerns about 
driving under its influence (R-squared = 0.442). The authors concluded that interventions and 
campaigns addressing social norms and risk perceptions of marijuana use would be successful.  
124 
 
Qualitative research methods are employed in SEF models of marijuana use to guide 
public health policy.  Aukje and colleagues (7) investigated the process of new policy 
implementation of medical cannabis in Massachusetts in 2012, when that state legalized medical 
marijuana under Chapter 369 of the Act of the Humanitarian Use of Medical Marijuana statute. 
Analyzing qualitative data generated from ethnographic field notes, media reports, public 
records, and in-depth interviews with medical marijuana dispensary stakeholders, health care 
professionals, and patient consumers,  and triangulated with a grounded theory approach, the 
investigators noted gaps in transparency, communication, and education in the transition from 
illegal to legal status under the Massachusetts statute that governed the regulations for patients 
and caregivers, and permitted certification of physicians and the registration of marijuana 
dispensary entrepreneurs. The principles of social reconstruction theory, which proposes that 
most of which passes for knowledge in society is socially constructed, particularly common 
sense knowledge that constitutes the reality of everyday life for most of its ordinary citizens (8) 
was used by Boeri and colleagues (9) to build acceptance of CBM, highlighting the 
interdependence of  social, environmental and individual biological determinants. 
The situation was not so different however in New York in 2014, when the Governor of 
NYS, The Honorable Andrew Cuomo, signed the Compassionate Care Act into law, establishing 
New York State’s Medical Marijuana Program (“Program”). Three years later, during his 
Executive budget address, Governor Cuomo directed the DOH in consultation with other NYS 
agencies, to evaluate the experience, consequences and effects of legalized marijuana in 
neighboring states and territories, and to review the health, criminal justice and economic 
impacts of regulating recreational marijuana in New York. The DOH report (10) concluded that 
the positive effects of a regulated marijuana market in NYS outweighed the potential negative 
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impacts. Areas that could be causes for concern could be mitigated with regulation and proper 
use of public education tailored to address key populations. Incorporating proper metrics and 
indicators will ensure rigorous and ongoing evaluation. Inspired by the lack of perspectives from 
entrepreneurs, health care professionals, pharmacists, educators, and medical cannabis patients, 
this qualitative research study was performed to address gaps in the Program, and make further 
health policy recommendations using a SEF approach.     
While an increasing number of patients are using cannabis for medical reasons, how can 
we know whether the health benefits gained with medicinal cannabis are worth the added cost? 
Cost-effectiveness analysis, as performed in the Chapter 2 study, compares the costs and health 
benefits of two or more interventions to determine their value. A treatment is considered cost-
effective when the ratio of incremental costs to incremental health benefits, known as the ICER 
is less than a health care payer's willingness to pay for the health benefit. Quality-adjusted life 
years expressed in QALYs, which incorporate both quality of life and longevity, are the 
recommended measure of health benefit. Conversely, treatment is considered dominated, and 
categorically not cost-effective, when it is less effective but more costly than an alternative and 
extendedly dominated when less effective treatment alternative to usual care with a lower ICER 
value. From a US health policy standpoint, $100,000 per QALY is a commonly accepted 
willingness-to-pay threshold, but expert opinion estimates that it likely ranges from $100,000 to 






Legalization of Medical and Recreational Marijuana 
 There are several compelling reasons to legalize medical marijuana. The first is to make 
it widely available for its medical benefits especially its analgesic potential. The second is to 
integrate it along with other CBM into the multidisciplinary approach to chronic pain perhaps not 
as primary therapy but as adjunctive, second- or third-line therapy based upon its anticipated 
cost-savings and improvement of patients’ health related quality of life (HRQoL). The third 
reason is to reduce physician and patient’s reliance on opioid pharmacotherapy, thereby 
stemming the growing opioid crisis in the treatment of chronic pain.   
 The broader question of legalization of marijuana for recreational use is beyond the scope 
of this dissertation. Doing so would replace illicit market production and distribution with an 
industry in which there could be rules and regulations in which farmers, intermediaries, and 
registered dispensaries, but not criminals would conduct the bulk of the trade. There are also 
means of liberalizing marijuana policy even without legalization. For example, use could be 
tolerated, but the production and sale limited to small amounts and treated as a civil violation.  
As far as concerns about marijuana’s potential for addiction, there is little crisis among 
recreational or medical marijuana users according to Caulkins and colleges (12) citing most self-
described users as experimenters who generally do not meet all of the criteria of the Fifth Edition 
of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders 
(DSM- V) (13) for drug dependence or substance-related disorder. Moreover, regular marijuana 
use does not necessarily indicate dependence. Caulkins and colleagues (12) cite self-reported 
surveys of recreational marijuana users that fails to support marijuana as a gateway to harder 
drugs such as cocaine and heroin.  
127 
 
 Putting aside the question of whether to legalize marijuana, there is generally broad 
agreement on how to legalize it and what policies would guide its formulation from a public 
policy standpoint. This would certainly include keeping prices close to current levels, 
minimizing industry incentives to encourage heavy use, limiting marketing, and discouraging the 
chemical composition of products to make it more appealing, and discouraging concomitant 
consumption of alcohol and nicotine. It is uncertain whether these guidelines would be necessary 
or even sufficient to prevent big increases in marijuana use or other negative outcomes.      
 Separating medical from recreational marijuana use is necessary in this political climate 
until the latter is legalized and destigmatized. The national trend toward legalization of medical 
cannabis took a turn first, during President Donald Trump’s campaign when he opined that states 
should have the right to manage their own policies with regard to medical and recreational 
marijuana (14), and three years later, when he voiced support for the Sates Act, a bipartisan bill 
that would effectively end the federal prohibition on marijuana and leave the issue up to the 
states (15).  
 By 2019, thirty-seven states legalized marijuana for medical use. Several of them  that 
legalized its recreational use, including Alaska, California, Colorado, Illinois, Maine, 
Massachusetts, Nevada, Oregon, Vermont, Michigan, and Washington and the District of 
Columbia, also petitioned the Federal government to enforce the 2013 Cole Memorandum (16). 
The latter assured states with some form of legalized marijuana use, that United States Attorneys 
would not prosecute users. This was rescinded by Attorney General Jeff Sessions in 2018 and 
replaced with the Sensible Enforcement of Cannabis Act, enshrining into law the protections 
offered by the memo (17).    
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Further Research  
As the majority of patients in placebo-controlled RCTs of medicinal cannabis are 
administered cannabis in addition to an existing pain regimen, there is support for exploratory 
CEA studies of medical cannabis as adjunctive therapy in the treatment of chronic neuropathic 
pain with and without cancer, using computer simulation to assess the cost-effectiveness of 
augmenting first-line, second-line, or third-line standard therapies for neuropathic pain in 
treatment-naive patients over 1 year from a US health care sector perspective.   
Pop stars hospitalized and others dying of opioid overdoses have refocused the nation on 
an epidemic of wide-ranging proportion that threatens the fabric of our values, and highlighting 
the disparity in the risk of recreation or medical cannabis use. Over the past two decades, opioid 
analgesics have become a leading pain management strategy and dispensing has tripled (18) in 
parallel, the incidence of opioid use disorder and opioid overdoses have both dramatically 
increased (19). To reduce these harms, patient groups, clinicians, and policymakers have called 
for new strategies to address pain management and reduce use of opioid analgesics. Bachhuber 
and colleagues (20) recently reviewed the state of research in chronic pain who might benefit 
from medical cannabis instead of opioids. This 2018 landmark study led to an important and 
rapidly expanding strategy to substituting medical cannabis for opioid medications in an effort to 
address the opioid epidemic.   
Several roadblocks remain to make cannabis a realistic and medically accepted 
alternative to opioids. The first is the gaps in research demonstrating unequivocal benefit in pain 
management using RCTs, which continue to face numerous hurdles because of the Schedule 1 
status of cannabis. Although the Drug Enforcement Administration (DEA) announced policy 
changes to expand the number of cannabis manufacturers, currently only one entity is authorized 
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to produce and supply cannabis to US researchers (21). The cannabis products available for 
research are limited in scope and not necessarily comparable to cannabis products available in 
state dispensaries. Even when products are obtained for research, they typically must be 
dispensed in a directly observed setting. Only a handful of US clinical trials have administered 
cannabis to examine its effect on pain, and all occurred in tightly controlled human laboratory 
settings at short distances and with small sample sizes of less than 100 participants (22-26).  
Notwithstanding, enrolling cannabis-naïve participants in a RCT could introduce 
significant biases due to its already broad use and the likelihood of participants to be invested in 
a positive outcome. Others might not be motivated to enroll in a RCT because of cannabis' 
widespread availability outside of the trial. Given current limitations of interventional research, 
observational studies are an appealing alternative. Longitudinal cohort studies of patient-reported 
pain outcomes are feasible, and even intensive assessments of pain have not been found to affect 
participants' responses (27). While longitudinal cohort studies that simply compare those who 
use medical cannabis to those who do not would be inescapably confounded, more complex 
designs and analyses could potentially come closer to estimating causation (28).  
The management of treatment-resistant chronic pain with medical cannabis has shown 
promise. Haroutounian and colleagues (29) conducted an open-label, prospective cohort of 274 
participants in which the primary outcome was a change in the pain symptom score and 
important secondary outcomes were pain severity, interference, social and emotional disability 
scores, and change in opioid consumption. At six month follow up, there were significant 
changes (p<0.001) in pain symptoms, severity and interference scores, together with social and 
emotional disability scores, and opioid consumption improved by 44% without serious adverse 
effects.  While each of these analyses has limitations, users of medical cannabis were less likely 
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to suffer than a general population of chronic pain patients and the treatment allowed a 
significant proportion of patients to discontinue opioid use. 
While experimental clinical trials provide the most definitive proof on any cause and 
effect relation between medical cannabis and reduced opioid use, such studies are difficult 
because its Schedule I substance status decrees it as having no currently accepted medical use 
and a high potential for abuse.  Other countries have similar restrictions that pose challenges for 
researchers to legally obtain cannabis or to get approval for clinical trials. Nonetheless, such 
trials are also a necessary next step because they would help determine safety. Thus, states with 
legalized medical cannabis need to be guided toward a policy on the ways that cannabis can be 
researched and accessed by the scientific community. 
An important next step for this dissertation research is to work collaboratively with Vireo 
Health to extend the findings of Chapter 4, and establish algorithms for patients seeking to wean 
off opioid drugs with adjunctive CBM. The goal of initially reducing a client’s opioid dose by 
20% in a controlled setting in collaboration with health providers and the dispensary pharmacist 
is achievable over a 2-month period of 10% per month and poses no health risk, and as shown in 
Chapter 2, is cost-effective. Using a mixed methods prospective cohort design, such a study 
could be performed in collaboration with Vireo health. The study would enroll 20 subjects on a 
stable dose of opioids for chronic neuropathic pain associated with cancer who agree to follow a 
protocol for weaning their opioid dosage with the introduction of CBMs into their pain 
management regime over a set timeframe. Lived experiences and emergent themes of the 
subjects could be examined with in-depth, semi-structured phone interviews at entry and exit, in 
conjunction with quantitative data collected monthly with regard to the dose of opioids and 
CBM, and triangulated with PEG and VAS scoring, QoL assessment, and demographic data. 
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Key Strengths and Limitations 
 In-depth interviewing was the primary study modality in Chapters 2 and 4. In the first 
study, it offered this investigator the opportunity to triangulate subjects’ interpersonal 
interactions in obtaining a referral to the dispensary after certification by NYS and obtaining 
cannabis at a dispensary, with their beliefs and experiences. This is preferable in public health 
policy to administering written or oral surveys where the investigator must hope to ask the right 
questions of a purposive convenience sample of subjects as in the pilot study of Chapter 2, to 
unveil essential information about the performance of NYS’ Program. As “qualitative research 
answers questions such as “what is X, and how does X vary in different circumstances, and 
why?”’ rather than “how big is X or how many X’s are there?” (30), the strength of in-depth 
interviewing would lead it to outperform the deductive approach of the quantitative research 
paradigm lest we test an exposure. Moreover, Chapter 2 was neither a study of a specific disorder 
treated by medical cannabis such as cancer-related neuropathic pain, nor was it comparing it to 
another agent, whether first- or second-line, such as opioids in Chapter 4.  By its very nature of 
allowing subjects to use their own voice and express their conviction (31) the results of in-depth 
interviewing in the pilot study of the feasibility of treating neuropathic pain in the cannabis 
dispensaries in Chapter 2 allowed this investigator to actively deduce hypotheses to study the 
cost-effectiveness of cannabis compared to opioids for SCD in Chapter 3, or test its utility in a 
SEF model in the management of cancer-related pain in conjunction with, or instead of opioids 
in Chapter 4.  
Notwithstanding, in-depth interviewing has predictable limitations in regards to design, 
implementation, and analysis that have already been previously reviewed. These include 
potential difficulties in design, preparing for, and conducting the interviews, the tools and 
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training necessary to carry it out properly; the subjectivity of responses by interviewees that is 
influenced by social norms due to perceived stigma, as well as the difficulty in replicating the 
findings and extrapolating and generalizing the results to a larger population. The selection 
process of subjects in our two interview studies was purposive and the study cohort in Chapter 2 
and 4 were chosen by Vireo Health pharmacists both because of their willingness to share their 
information and experiences. While such samples have the benefit of convenience, they do not 
assure, as in random sampling, that the results will generalize to the population from which they 
were drawn, in these instances, neither the entire pool of Vireo Health dispensary users, nor all 
participants in New York State’s Program. Neither study cohort was chosen because of a need to 
address a specific policy question avoiding intentional skewing of the sample. Both cohorts were 
relatively small which could have negative impact on the significance of the data, and further 
affected by dropouts but there was no attrition.   
The number and location of the dispensaries of the studies in both studies imparted key 
strengths and weaknesses. More than one Vireo Health downstate dispensary participated in the 
study of Chapter 2, while only one upstate dispensary took part in the Chapter 4 study.  The 
greater geographic representation in the former study likely instilled more divergent life 
experiences and opinions. This was added to the opportunity for study subjects to meet more 
than one pharmacist. In that regard, the results in Chapter 2 yielded a likely more valid 
assessment of the Program and less so that of the dispensary alone while limiting the latter study 
to a single dispensary location and pharmacist in upstate New York would instill greater 
consistency controlled for the prescribing behaviors of more than pharmacist in the choice of the 
cannabis product and dose. The dispensary in Upstate New York was in a more rural, remote and 
less affluent setting than the downstate New York dispensaries making them non-comparable.     
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An important limitation of the study in Chapter 4 was the onset of the COVID-19 
pandemic. Pursuant to the February 24, 2020 executive order of NYS Governor, Honorable 
Andrew Cuomo, citizens were asked to shelter-in-place and social-distance especially for the 
elderly especially those with comorbid diseases such as cancer. Most physicians were advised to 
practice via Telemedicine and similarly Vireo Health conducted remote visits via the internet. 
Study subjects probably experienced a greater degree of isolation and many were at risk for 
being lost to follow up by their health professionals. It was at this junction that the decision was 
made to terminate data collection mainly after the entry interview. This did not preclude 
assessing the dispensary records of drug doses and any emerging trends in the tapering of opioid 
drugs concomitant with medical cannabis. There is no means of knowing the true impact of the 
pandemic on our subjects without carrying out detailed interviews on that subject. However, 
given the widespread alarm of devastating morbidity and mortality, it is very likely that the 
subjects, like other normal citizens, were significantly distracted and fearful of contracting 
COVID-19. Given the extensive publicity, it was well known that patients with comorbid disease 
were at higher risk of infection and mortality mandating stricter adherence to isolation 
precautions. The poorer prognosis of patients with cancer and COVID-19 infection results from 
the systemic immunosuppression of a past or present malignancy and recent anticancer treatment 
(32). Cancer patients followed at home represent a particularly frail population. Although with 
substantial differences, the challenges, which cancer care professionals have to face during a 
pandemic, are quite similar to those posed by natural disasters. Such patients, especially those 
with lung cancer, should undergo vigorous screening for COVID-19 infection and avoid 
unnecessary treatments that could alter their immune competence or have their dosages 
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decreased in case of COVID-19 co-infection or altered immune competence (33). Thus, there 
was reason to consider halting the study based upon medical caution.  
The CEA of Chapter 3 compares medical cannabis to opioid medication using SCD as a 
surrogate for chronic neuropathic pain. There are utility measures of HRQoL for SCD allowing a 
comparison of both positive and negative effects of an intervention expressed as QALYs gained 
or lost. The latter is a surrogate for the combined effects of QoL and overall health as measured 
by a uniform rating scale, standard gamble, time tradeoff, or willingness to pay. By deriving 
QALYs gained or lost to the relative costs of adding medical cannabis to the standard of care for 
opioids in the treatment of SCD with the goal of reducing the dose of the latter by 20%, it was 
possible to calculate cost-savings for this intervention. There were several key limitations to this 
model. First, the presumption that a reduction of the opioid dose of 20% is achievable is well 
established but there are no anecdotal or RCT of its health outcome either in terms of later opioid 
addiction or outcome of SCD, or the presumptive effect societally on the opioid epidemic, 
Second, this was a theoretic experiment modeled on 2017 US$ that did not include financial 
costs associated with non-chronic pain SCD-related healthcare costs, or healthcare costs of 
opioid overdose and addiction treatment. Third, the analyses did not include potential societal 
costs associated with opioid addiction including productivity loss and costs incurred in the 
criminal justice system. The inclusion of these costs would likely have further improved the 
favorable cost-effectiveness of medical cannabis treatment. As further studies are performed in 
the study of chronic pain in SCD, the sensitivity analyses in this study can be used to estimate 
whether medical cannabis treatment is sufficiently effective to be cost-effective.  Fourth, the 
present CEA model did not evaluate adverse event rates. This could be obtained for future 
studies based upon published prospective studies of cannabis for chronic noncancerous and 
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applied to probability inputs to compare with conventional analgesia therapies. Finally, the CEA 
was not modeled to ascertain the cost-effectiveness of augmenting first-, second, or third-line 
standard therapy in SCD or the ideal choice of CBM product or dose. Awaiting detailed data 
from published RCTs in neuropathic pain disorders for which cannabis is accepted therapy, it 
will be necessary to extrapolate from other cohort studies, including the modeling experience in 
Chapter 3 of SCD, and the dispensary-based study in Chapter 4 of cancer-related neuropathic 
pain.   
 
Public Health Relevance 
 Political ideology, conflicting medical evidence and opinions and media attention have 
all affected the formulation of public health policy of medical cannabis. Recognizing that 
caregivers and patients look for treatment options for unmet medical needs, in one rare instances, 
the FDA recently approved the purified cannabidiol Epidolex®, produced by GW 
Pharmaceuticals for the treatment of refractory seizure disorders in children age ≥2 years due to 
severe  myoclonic epilepsy of infancy, and Lennox-Gastaut syndrome. There are pathways for 
expanded access and compassionate use of cannabinoids in the treatment of refractory seizures 
due to infantile spasms and tuberous sclerosis complex by the same pharmaceutical 
manufacturer. Patients with glaucoma, neuropathic pain, cancer, MS, chemotherapy-induced 
nausea, and other seizure disorders, for which clinical trials have shown efficacy of medical 
cannabis, await FDA approval. However, failing to legalize medical cannabis, the US DEA, 
which continues to list medical cannabis as a Schedule 1 agent, and lists marijuana as an agent 
without medical use, adds to the difficulty of states’ legislators to implement regulations 
governing the dispensation by credentialed health care providers to patients with certified needs 
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(34, 35).  The diversity in the way that states have regulated medical cannabis as regards to the 
permissible amount an individual can possess, as well as differences in the pathways for 
provider, dispensary and patient registration and certification to be eligible for participation, and 
perceptions surrounding its legitimate use, collectively add to the complexity in forming a 
unified public health policy.   
While the medical community and legislators debate the merits of marijuana reform, 
legalization is advancing across the United States. While still prohibited under federal law, 
medical marijuana is now legal in more than one-half the states, and in 8 states, medical cannabis 
can be purchased by anyone older than 21 years. Federal support of state cannabis laws is critical 
for the millions of patients who require the medication. Despite the contentious divisions in 
American politics, marijuana legalization has found bipartisan support. The government’s own 
statistics explain the decades-long, steady shift in public opinion. Every year, the US makes 
575,000 arrests for marijuana possession alone, which is greater than the number of arrests for all 
violent crimes combined (36). Enforcement of marijuana laws disproportionately affects our 
nation’s poor communities of color, contributing to the crisis of mass incarceration. The war on 
marijuana exacerbates poverty and has the potential to reduce the access to health care. The 
unjust prohibition of marijuana has done more damage to public health than has abuse of the 
marijuana itself. 
The case for decriminalization of marijuana and legalization of medical cannabis among 
physicians, according to Nathan and colleagues (37) is unsettled. While many physicians who 
oppose legalization of medical cannabis continue to support legislation to decriminalize 
marijuana, there are many serious problems with that position. Decriminalization prevents the 
government from regulating product labeling and purity, leaving marijuana vulnerable to 
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contamination and adulteration. Without knowing its potency, consumers are unable to use it 
responsibly. Decriminalization still leaves marijuana in the hands of drug dealers and not 
responsible vendors, and prosecutes marijuana growers and sellers thereby constricting the 
supply chain and driving up its price, sustaining it as a lucrative untaxed illegal product and 
providing market incentive for more competitive and violent procurement. 
Contrary to the policy of alcohol prohibition that historically was repealed after only 13 
years, physicians have advocated for effective regulation. Doctors for Cannabis Regulation 
(DFCR), a national organization of physicians dedicated to the legalization and regulation of the 
adult use of marijuana published a declaration of principles for medical cannabis regulation (38) 
citing that the vast majority of adults are unharmed by the responsible use of cannabis and the lack of 
evidence that cannabis is a gateway for later use of more harmful drugs. Legalization encourages honesty 
in patient-doctor communication about cannabis use. Properly structured, tax revenues from cannabis 
sales can fund research, education, substance abuse treatment programs, and community reinvestment. 
Legalization would reduce the disproportionate impact of the criminal justice system on low-
income and minority citizens. Regulation benefits public health by enabling government 
oversight of the production, testing, labelling, distribution, and sale of cannabis. An end to 
prohibition creates the legal distinction between underage and adult use, differentiating its use by 
responsible adults. 
Concerned physicians advocate cannabis packaging and advertising that targets adults 
and prohibits underage use by minors enforced by child-resistant packaging and strong penalties 
for those who enable its use in children. Informed physicians may disagree about the specifics of 
good regulation, but we cannot abstain from the discussion. As cannabis growers and 
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pharmaceutical experts advise lawmakers on its regulation, there is an increasing need for 
physicians to do so as well.  
The challenge for the emerging marijuana industry is to raise standards and promote 
patient and physician satisfaction. Up until now, there has been inconsistent evidence that the 
industry has made efforts to conduct quality assurance activities. Some dispensaries promise that 
they measure and warrant the chemical composition of each batch of their products. A 
reasonable generalization regarding the current state of affairs, however, is that the cannabis that 
patients purchase at the local cooperative will likely contain uncertain concentrations of 
THC/CBD and other compounds, despite what the label says. A study of 75 products randomly 
purchased from internet-listed dispensaries in San Francisco, Los Angeles, and Seattle showed 
accurate labeling of THC/CBD content in only 17% (39). The majority (60%) were over-labeled, 
(at least 10% less cannabinoid content than claimed), while 23% were under-labeled (at least 
10% more cannabinoid content than labeled).  This fact raises a host of other considerations, 
including basic safety (might there be the presence of adulterants, congeners, contaminants, 
insecticides), dose-related concerns (little or no pharmacologic effect at one end and drug-related 
toxicities at the other), and potentially differing pharmacologic effects from batch to batch, just 
to name a few. It also adds an additional level of uncertainty to any efforts by the clinician to 
consider/discuss/counsel patients about dose, drug–drug interactions, and other routine clinical 
issues that might arise around the prescription or endorsement of a new treatment. 
         Increasing physician comfort in signing endorsements, attestations, or certifications of the 
possible efficacy of medical marijuana for a particular problem or symptom is an important goal 
for the marijuana industry. Equally vital is attracting physicians to perform case reviews and to 
complete the attestation paperwork that allows patients to purchase a medical marijuana ID card, 
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which will then allow their patients to gain admittance and to purchase from a certified 
dispensary. By reducing the uncertainty about whether the chemical composition of what 
patients believe they are, purchasing is in fact that which they are being sold will allow ordering 
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Interview Instrument for Chapter 2 
I am interviewing you today as part of City University’s research study of New York 
State’s Medical Marijuana Program. The purpose of today’s interview is to learn about the 
experiences of various stakeholders involved and impacted by the process of legalization. By 
understanding the factors that may shape this process from the perspectives of various 
stakeholders, this study will highlight what is being done and provide recommendations for both 
policy and future research. 
I want to start by asking you some questions, this interview is meant to be an informal 
conversation and you are encouraged to diverge into any areas that you feel are important to the 
topic. With your permission, I will be audio recording this interview. This recording will be 
confidential. We will not include your name or any other identifying information on the 
transcript. Rest assured, the information, data, and reports that may come from this study, and 
our interview today, cannot be traced back to you. Your participation in this study is voluntary. 
You may refuse to answer any question or end the interview at any time without penalty. 
Therefore, if at any point you need me to turn off the recorder, please feel free to say so. 
We ask people to choose a pseudonym, or a fake name, that we can use for your story. 
We include this name on the tape so your real name is not attached to any of this information. 




INTERVIEWER: State the following information after you turn on the recorder:  
1.   Interviewer (your) name 
2.   Respondent’s pseudonym 
3.   Date 
Ice Breaker 
First, I would like you to tell me a little bit about yourself without revealing specific 
information that would identify you. So, can you talk about yourself in terms of what you are 
doing at this time in your life, your goals, and any major experiences that affected your life so 
far? Thank you for sharing this with me. Let us start talking about the topic of this study, medical 
marijuana. 
Personal Views  
1.   Can you describe what you know about medical marijuana (MM) and medical 
marijuana legalization (MML)? 
2.   Can you speak a little bit about your views regarding MM before the MML bill 
passed? [Probe: indifference, concern, advocate, activist, experiences] 
3.   Can you describe any ways in which your views have changed since the bill passed? 
4.   Can you speak a little bit about your views regarding the recreational use of 
marijuana? 
5.   Can you describe your views on regular use of marijuana? [Probe: for yourself, your 
friends, and your family members] 
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6.   Can you describe your views on the concept of marijuana as a “gateway drug”? 
7.   Can you speak a little about your views regarding medical marijuana dispensaries 
(MMD) opening in this state? [Probe: diversion, dependence issues, crime] 
8.   Can you speak a little about how you feel about a MMD opening near where you 
live? Where do you go to school or work? 
9.   What does the trend toward MML mean to you? [Probe: recreational marijuana, legal 
repercussions, health repercussions] 
10. What does the trend toward legalizing marijuana mean to you? [Probe: other drugs, 
social repercussions, health repercussions] 
Community Norms and Attitudes  
11. Can you describe what you know about how MMLs affected states that passed MML 
bills already? [Probe: positive impact, negative impact; research; debates] 
12. Can you describe what you know about the process for implementing MM here in 
New York? How did you learn this? [Probe: NYSDOH regulations; registration, public 
meetings] 
13. Can you describe what you know about the process for opening a MMD here in New 
York? [Probe: NYSDOH regulations; registration, controversies] 
14. What, if anything, have you heard about in your community (friends, parents, school) 
regarding a MMD opening? [Probe: In the community, nearby, bans, moratoriums, 
commercial boost; crime] 
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15. Can you describe for me the community where you live and the community where 
you go to school or work? [Probe: social and economic environment; political 
environment] 
16. In your opinion, how will a MMD opening in or near where you live impact the 
community? Where do you go to school or work? [Probe: no impact, negative, positive, 
not sure, Why?] 
17. In your opinion, how do you think the members of the community where you live 
would feel about an MMD opening there? The community where you go to school or 
work? 
18. Can you talk about who you see as the main people who will be impacted by MM in 
the community where you live? Where do you go to school or work? [Probe: students, 
younger youth, drug users, homeless, criminals, commercial owners] 
19. How will a MMD opening in the community where you live affect you? Where do 
you go to school or work? [Probe: no impact, negative, positive, not sure, Why?] 
20. Can you describe anything you have heard and your own opinions regarding dangers 
associated with a MMD? Of MM? Of marijuana? 
21. Can you describe any side affects you know of or have heard of with the use of MM? 
Can you describe how these might be resolved?  
Personal Norms and Attitudes and Behaviors  
22. Can you speak a little bit about the health problems you think MM may be used to 
treat and why? [Probe: personal experiences, hearsay] 
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23. Can you describe what you know about the process of obtaining a medical marijuana 
registration card? About where MMDs will open? 
24. Can you describe anything you have heard and your own opinions on MM causing a 
user to engage in more risky behaviors than typical? 
25. Can you describe anything you have heard and your own opinions on recreational 
marijuana use causing a user to engage in more risky behaviors than typical? [Probe: 
sexual behaviors, multiple partners, drug injection behaviors] 
26. Can you describe any impact you think MM will have on youth in this state? [Probe: 
interest, diversion, dependence, behaviors] 
27. In your opinion, is there a need in terms of prevention services for young people who 
might have problems with marijuana use? If so, what is the most important need for 
addressing this? 
28. Can you describe any health problems that you would like to use MM to treat? 
29. Can you talk about any plans you have to get a MM registration card and why? 
30. Can you talk about anyone you know who will be trying to obtain a MM registration 
card. If so, how do you know this person? What do you think of their reasons for needing 
a MM card? 
31. Can you describe a time, if any, that you have obtained marijuana from someone who 
used it for medical purposes? If so, please describe how you obtained it. How did you 
feel about using MM illicitly? [Probe: fearful, paranoid, indifference, content, worth-it] 
32. Do you think smoking marijuana regularly can be harmful? In what ways? 
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33. Can you describe how easy it would be for you to obtain marijuana right now if you 
wanted it? 
34. What do you think your close friends think about using medical marijuana? About 
smoking marijuana for recreational purposes? About using it regularly? 
35. If you plan to apply for a registration card, how do you think this will affect your life? 
Your future? Your parents? What are your concerns? [Probe: legality, diversion, 
dependence, cost]  
Physician Specific Questions  
36. Can you describe the process of prescribing MM to a patient? 
37. Can you discuss how comfortable you are with prescribing MM to a patient? 
38. Can you describe the process of being registered to prescribe MM? 
39. How comfortable do you think most physicians you know would be with becoming 
registered? In addition, with prescribing MM to a patient? Why?  
Patient Specific Questions  
40. Can you describe what you know about cost, insurance coverage, and financial 
subsidies for MM? 
41. Can you discuss how comfortable you are with talking with your physician about 
MM?  
Pharmacy Manager Specific Questions  
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42. Can you describe the process of being able to dispense MM? 
43. Can you describe what you know of the cost structure, insurance coverage, or 
financial subsidies for MM?  
Great! Now if we can just wrap up with a few standard demographic questions for context.  
Demographics  
1.   What is your gender? 
2.   What is your age? 
3.   How would you describe your religion? 
4.   What kind of area were you raised in? Urban/rural/suburban/small town? 
5.   How would you describe your political orientation? 
6.   How would you describe your current employment status? 
7.   Can you estimate your household’s combined annual incomes in thousands? 
8.   Where do you live? (Town/neighborhood) 
9.   What is the highest level of school you have completed or degree you have obtained? 
10. How would you describe your ethnicity?  




PEG Pain Scale 
 







Interview Instrument for Chapter 4 
You are being asked to participate in a research study because you and your physician 
have agreed to follow a protocol of using medical cannabis to manage your cancer-related pain 
while weaning down on your opioid dosage. 
  Purpose: The purpose of today’s interview is to learn about the lived experiences of 
patients in New York with cancer-related pain management strategies, specifically the 
experience of using medical cannabis to manage cancer-related pain while reducing opioid 
dosage. In the first interview, this study seeks to understand your experiences with an opioid-
driven pain management strategy. The interview will be repeated at the end of the three months 
in which you, your physician and your Vireo Pharmacist have followed a protocol of weening 
your opioid dosage down by introducing medical cannabis into your pain management strategy. 
Each interview will ask in-depth questions about your health, experiences of pain and side 
effects, and quality of life. If any of these questions are uncomfortable or sensitive for you, you 
may wish to stop and withdraw from the research study. By gaining a clearer understanding of 
the contexts and lived experiences of patients managing chronic cancer-related pain with opioids 
and medical cannabis, this research study will highlight what is currently being done for 
improving pain management options and provide recommendations for health policy, 
interventions and future research to help improve pain management options. 
  
Key Information: Before we begin, I want to ask for your consent to participate in this 
research study. I would like to reassure you that your participation in this study is voluntary and 
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you may quit the protocol, refuse to answer any question or end the interview at any time, or 
remove yourself from the study without penalty or any negative impact on your relationship with 
Vireo Health. Before you begin and after you complete the three-month protocol for reducing 
your opioid dosage with medical cannabis, we will ask you to participate in a phone interview to 
document your experiences with this process. If you choose to end the protocol early, we would 
still like to conduct an exit interview with you as your experiences and choice to discontinue the 
opioid reduction would be important to our research and understanding. Each of the two 
interviews will be conducted over the phone and last no longer than one hour. Consent will be 
audio recorded prior to each interview. During the course of these interviews, we may be 
touching on topics that are sensitive, including topics such as illicit drug use and experiences of 
mental health issues. You do not have to answer questions that make you feel uneasy or 
embarrass you, can skip any question or end the interview at any time. Your participation in this 
research will add to a greater understanding of pain management options for cancer-related 
chronic pain patients and contribute to recommendations for protocols for reducing opioids and 
policy regarding medical cannabis for pain management. 
Procedures: If you volunteer to participate in this research study, we will ask you to do 
the following: 
  
1.   Participate in two, one-hour long in-depth phone interviews covering topics related to 
your quality of life, health, and opinions and experiences with medical cannabis. Topics covered 
will include occupation, social life, mental health, pain management strategies, health care 
utilization, and your opinions and experiences of medical cannabis. 
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 2.   Consent to your Vireo pharmacist sharing de-identified data on your opioid and medical 
cannabis dosages as well as your pain scores over the research study period. The data on dosage 
and pain scores for all participants will be shared in a batch and names and identifying 
information will be removed before they are shared to ensure that data cannot be matched to 
individual study participants. This data will be used to conduct a cost-effectiveness analysis of 
the opioid reduction protocol. 
Audio Recording: To ensure the accuracy of the findings, the in-depth phone interviews 
will be audio recorded for later transcription and analysis. You may at any time request that I 
turn the audio recording device off without penalty. 
  Time Commitment: Your participation in this research study is expected to be two hours 
in duration over a total of three months. 
Potential Risks of Discomforts: During the course of the in-depth interviews, you may 
find some questions ask you to describe aspects of your life or experiences that you find 
sensitive, stressful or embarrassing. Discussing your state of health, symptoms, pain 
management strategies and the impacts of these things on your daily quality of life may because 
you discomfort. 
  
Potential Benefits: You will not directly benefit from your participation in this research 
study. 
  Payment for Participation: You will receive a $50 amazon gift card after your 
participation in each of the two in-depth interviews, totaling $100. 
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  New Information: You will be notified about any new information regarding this study 
that may affect your willingness to participate in a timely manner. 
  Confidentiality: Best efforts will be made to maintain confidentiality of any information 
that is collected during this research study, and that can identify you. This information will only 
be disclosed with your permission or as required by law. 
  The audio recordings of the interviews will be listed under a pseudonym and kept on a 
password-protected computer in my possession. The transcript made from this recording will be 
identified by pseudonym only and any identifying content will be coded in the transcripts. I will 
not include your name or any other identifying information on the transcript. 
  The research team, authorized CUNY staff, and government agencies that oversee this 
type of research may have access to research data and records in order to monitor the research.  
Research records provided to authorized, non-CUNY individuals will not contain identifiable 
information about you.  Publications and/or presentations that result from this study will not 
identify you by name. 
  We might remove identifiers from the information collected from you as part of this 
study and use it for future research studies or distribute it to another investigator for future 
research studies without additional informed consent. 
  Participants’ Rights:   
•      Your participation in this research study is voluntary. If you decide not to participate, 




•      You can decide to withdraw your consent and stop participating in the research at any 
time, without any penalty.  
Questions, Comments or Concerns:  If you have any questions, comments or concerns 
about the research, you can talk to one of the following researchers:  
•      David Younger, MD MPH MS, primary investigator on research study and doctoral 
candidate at CUNY School of Public Health and Health Policy, 
David.younger89@sphmail.cuny.edu 
•      Betsy Eastwood, PhD MSW, faculty advisor on research study and professor at CUNY 
School of Public Health and Health policy, Betsy.eastwood@sph.cuny.edu 
If you have questions about your rights as a research participant, or you have comments or 
concerns that you would like to discuss with someone other than the researchers, please call the 
CUNY Research Compliance Administrator at 646-664-8918 or email HRPP@cuny.edu.  
Alternatively, you may write to:  
  
CUNY Office of the Vice Chancellor for Research 
Attn: Research Compliance Administrator 
205 East 42nd Street 
New York, NY 10017 
Participant Oral Consent: With your consent, I will now turn on the audio recorder and 
record your oral consent. After I turn on the audio recording, I will ask you if you agree to give 
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consent for both audio recording of your interview and for participating in the study and record 
your answers. 
I also ask participants to choose a pseudonym, or a fake name, that we can use for your 
story. I will include this name on the audio recording, so your real name is not attached to any of 
this information. What would you like your pseudonym to be? 
  Pseudonym: ___________________________ 
  
Can I turn on the recording device now? 
[If the participant gives consent, turn on the audio recording device] 
Interviewer states the following information after turning on the recorder: 
1) Interviewer name 
2) Respondent’s pseudonym 
3) Date 
Participant Oral Consent for Audio Recording: 
Do you agree to audio recording of this interview? 
Participant Oral Consent for Participation: 
Do you agree to participate in this research study? 






Before we begin, do you have any questions? 
Is it okay if we get started? 
Great, let us start with some questions regarding your health and healthcare. As a reminder, 
you may skip any question or end the interview at any time without repercussion: 
State of Health 
·         Can you tell me a bit about your health history? 
·         Can you tell me about your current state of health? 
o   What diagnoses are you currently living with? 
o   Can you describe your current symptoms and levels of pain? 
o   How do these conditions and their associated symptoms impact your daily 
routines and activities? [Probe: activities may include exercise, lifting, 
climbing stairs, walking, bending, bathing, dressing, driving, work-related 
activities, etc.] 





·         Can you describe for me what your current pain management strategy includes? 
[Probe: Prescribed medications, self-medication, alternative therapies, home 
remedies, etc.?] 
·         Can you describe any changes your pain management strategy has undergone and 
what those experiences have been like for you? 
o   Can you tell me about any experiences of withdrawal you have had as a 
result of changes in your pain management strategies? 
o   Can you describe why you have changed your pain management strategy? 
·         Can you tell me a bit about the side affects you experience from your pain 
management strategy? 
o   Have these side effects changed over time? 
o   Have these side effects changed with medication used? 
·         What does it mean to you to be living with cancer-related chronic pain? 
o   Does it affect your life? 
o   Does it affect how you see yourself? 
o   Does it affect how others treat you? 
Health Care Utilization 
·         Can you tell me about how often and when you use health care services? 
·         What things influence why and when you will see a doctor or seek health care? 
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·         Can you describe the processes that you go through to gain access to your pain 
management medications? 
o   Can you describe the process you went through to be prescribed opioids? 
Medical cannabis? 
o   Can you tell me about how you fill these prescriptions and get your 
medications? 
·         Can you describe what you know about cost, insurance coverage, and financial 
subsidies for opioids and medical marijuana? 
Great, let us move on to some questions about your life, your work life and your social life: 
Occupation 
·         Can you tell me about you work history? 
·         Can you describe for me your current work life? [Probe: full-time, part-time, 
unemployed, self-employed, student? Are the hours regular, variable, flexible?] 
·         Can you tell me a bit about how you feel about your work situation? 
o   Are you comfortable at work? 
o   Do you feel secure in your situation? 
·         Can you describe for me any ways in which your health affects you work life? 
[Probe: cut down amount of time spent at work, alterations in work activities, 




·         Can you tell me about your social life? [Probe: what is your social network like? 
How often do you go out?] 
·         Can you tell me a bit about your feelings regarding your social life? [Probe: do 
you feel you have enough of a support network? Are you happy with your level of 
engagement with friends and family?] 
·         Can you describe for me any ways in which your current health affects your 
social life? 
·         Can you tell me about any issues of depression, loneliness, anxiety, or stress you 
have experienced? 
o   What do you think were the reasons behind these experiences? 
o   How did you deal with the issue? 
o   Did you access any health care resources when dealing with the issue? Why 
or why not? 
 Great, now I have just a few more questions about your opinions and those of people you know 
regarding marijuana. 
 Norms and Attitudes Regarding Medical Marijuana 
·         Can you describe your views on regular use of marijuana? [Probe: for yourself, 
your friends, and your family members?] 
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·         Can you speak a little about your views regarding medical marijuana dispensaries 
(MMDs) opening in this state? [Probe: diversion, dependence issues, crime] 
·         What does the trend toward MML mean to you? [Probe: recreational marijuana, 
legal repercussions, health repercussions] 
·         Can you discuss how comfortable you were with talking with your physician 
about medical marijuana? Did you suggest it? Did you provider suggest it? 
 Miscellaneous 
·         What would you describe as the greatest challenge for chronic pain management 
facing cancer patients? 
·         Do you have any suggestions for what may be beneficial for overcoming this 
challenge? 
·         Are there any topics that we did not cover in this interview that you would like to 
discuss? 
 Thank you so much for taking the time to participate in this research study.  
 
 
  
  
 
 
